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ABSTRACT 
Obesity, insulin resistance and hypertension are risk factors for cardiovascular 
disease which occur in association more than individually in the general population; this 
clustering of symptoms is called Syndrome X. The association between hypertension and 
insulin resistance in this syndrome has traditionally been attributed to the effect of 
increased circulating insulin on sympathetic nerve activity and renal sodium retention. 
However, it has been shown that insulin exerts a direct vasodilatory action on the 
vasculature, which may be impaired in insulin resistant states. Studies in our laboratory 
have revealed that this vasodilatory effect is, in part, due to insulin stimulation of 
calcium pumps involved in extrusion of calcium from the cytosol. It is reported herein 
that recovery from agonist-induced intracellular calcium transients is impaired in vascular 
smooth muscle from insulin deficient streptozotocin-induced diabetic rats and insulin 
resistant obese Zucker rats. The obese Zucker rat is a genetic model of obesity, insulin 
resistance and hypertension carrying two mutant fatty (fa) alleles. Siblings carrying one 
or zero copies of the fa allele have been considered lean. However, there appear to be 
intermediate phenotypes in heterozygous lean animals which may be sensitive to 
environmental manipulations. The interaction of genetics and environment is an 
important area for study, as many disease processes are influenced by both. 
Consequently, studies were conducted to assess the effects of high fat feeding on rats 
carrying zero, one or two copies of the fa allele. Results indicate t�e presence of gender, 
genotype, and diet interactions. The fa allele does not appear to be recessive, and male 
animals carrying one copy of fa are more susceptible to the deleterious consequences of 
high fat feeding than female siblings or those carrying zero copy of fa. Hence, the 
heterozygous lean Zucker rat appears to be an appropriate model to study diet-gene 
interactions with respect to cardiovascular risk. 1v 
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PART 1 
INTRODUCTION 
1 
I. INTRODUCTION 
Cardiovascular disease is a prevalent problem in industrialized societies. Several 
large epidemiological studies since the 1970s have shown links among risk factors of 
cardiovascular disease and mortality (1 - 3). In the largest study thus far, 1.8 million 
Noiwegians exhibited a mortality curve for cardiovascular disease that was U-shaped 
when considering body mass index (BMI), with lowest risk at a BMI of 23 and a 2% 
increase in mortality with each kilogram increase in body weight (3). Data from the San 
Antonio Heart study showed that 287 subjects out of 2930 had high blood pressure and 
many of these also exhibited non-insulin dependent diabetes or impaired glucose 
tolerance and obesity. ( 4). Several other epidemiological, cross sectional and longitudinal 
studies demonstrate the same clustering of risk factors accompanying cardiovascular 
disease (3). 
In 1988, Reaven described a clustering of risk factors associated with 
cardiovascular disease which he called Syndrome X. The risk factors included 
hyperlipidemia, hypertension, and hyperinsulinemia (5). Obesity, localized to the 
abdominal body cavity and associated with androgen levels in men and women, has also 
been frequently observed (6). In addition, cellular insulin resistance has been associated 
with non-insulin dependent diabetes mellitus (NIDDM), hyperlipidemia and hypertension 
(6). 
The inter-relationships of these risk factors, as well as cause and effect questions, 
have been the focus of many recent studies. These coexisting conditions are likely 
influenced by both genetics and environment. The contribution to pathology of various 
abnormal genes has been demonstrated in both human and animal studies of obesity, 
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insulin resistance and hypertension (7 - 10). In addition, environmental factors such as 
high fat or salt diets and exercise are known to modulate one or more of the clustered 
risk factors ( 11 - 21 ). 
Many diseases result from factors in an organisms environment, imposed on a 
background of genetic susceptibility. Thus, there is a continuum of pathological 
observations influenced by a number of genes and variable environments. The interaction 
of genes with environment in cardiovascular disease has been studied by few; therefore, 
more attention is currently being focussed on the contributions of each, and how they 
may be modulated together, or separately, to reduce morbidity and mortality. 
The association of hypertension with insulin resistance has generally been 
attributed to increased sympathetic activity and renal sodium retention occurring 
secondary to hyperinsulinemia in obesity and NIDDM (6). However, recent studies 
suggest that insulin instead has a vasodilatory action which is directly impaired at the 
target tissue level (22 - 27). The target tissue of insulin, in this case, is not a 
traditionally accepted insulin effector such as skeletal muscle, adipose or liver, but is 
instead vascular smooth muscle. 
Increased blood pressure may be caused by increased total peripheral resistance 
which is determined by vascular smooth muscle contraction. The state of contraction of 
smooth muscle is, in part, dependent on the intracellular calcium concentration (28) 
which has been shown in several studies to be affected by insulin (29 - 38). Insulin has 
been shown to play an important role in intracellular calcium regulation in erythrocytes 
and vascular smooth muscle cells (29 - 38). Consequently, insulin effects on vascular 
tone in light of variable genetic and environmental backgrounds is a rich area for study. 
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II. RATIONALE 
It is known that insulin causes vasodilation and that insulin affects calcium 
metabolism in cultured vascular smooth muscle cells (VSMC). However, it is not clear if 
calcium metabolism is functionally altered in VSMC from insulin resistant or deficient 
animals. Therefore, the intracellular calcium responses of enzymatically isolated VSMC 
from insulin resistant (obese Zucker) and deficient (streptozotocin-induced diabetic) rats 
to pressor agents must be compared with VSMC from control animals. Freshly isolated 
cells maintain in vivo characteristics representative of the disease state which may not be 
present in cultured cells, however, damage may occur as a consequence of the enzymatic 
digestion procedure. 
The interactions of genetics and environment in Syndrome X are not understood, 
however, there are animal models which can be used to further investigate these 
relationships. The obese Zucker rat (fa/fa) is a well known genetic model of obesity, 
insulin resistance and hypertension. However, it is not possible to genotype these 
animals and thus the effects of one mutant gene in lean heterozygote (Fa/fa) siblings 
have not been examined. The study of early development and environmental interactions 
with the fa allele must be examined in offspring from a Brown Norway /Zucker cross 
which can be genotyped. Studying the effects of a single loci against varied genomic 
background is a limitation of this model, however, statistical procedures utilized here are 
aimed at controlling for genetic variability by accounting for litter effects. This model 
may be useful for studying the relationships among obesity, insulin resistance and 
hypertension from the molecular level to the whole animal. 
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III. OBJECTIVES 
The purpose of this dissertation is threefold: 1) to help elucidate the actions of 
insulin on vascular smooth muscle, which may alter cellular contractile activity and thus 
peripheral vascular resistance, in VSMC from insulin resistant (Zucker obese rats) and 
insulin deficient (streptozotocin-induced diabetic rats) animals; 2) to investigate the 
effect of dietary fat on the development of hypertension associated with obesity and 
insulin resistance; 3) to determine if there exists a gene dosage effect of the fa allele 
which may be modulated by environment ( dietary manipulations) in a new animal model. 
5 
LITERATURE CITED 
1. Alexander J, Dustan HP, Sims EAH, Tarazi: Report of the Hypertension Task 
Force, DHEW Publication No. 70-1631 (NIH), 1979; 9:61-77. 
2. Stamler RA, Stamler J, Riedlinger WF, Algera G, Roberts RH: Weight and 
blood pressure findings in hypertension screening of 1 million Americans. JAMA 
1978; 240:1607-1610. 
3. Larson B: Obesity, fat distribution and cardiovascular disease. Int J Obesity 
1991;1553-57. 
4. Ferranninni E, Haffner SM, Stem MP. Essential hypertension: An insulin­
resistant state. J Cardiovasc Pharmacol 1990;15:S18-S25. 
5. Reaven GM: Role of insulin resistance in human disease (syndrome X): an 
expanded definition. Annu Rev Med 1993;44:121-131. 
6. Reaven GM: Role of insulin resistance in human disease. Diabetes 1988;37:1595-
1607. 
7. Saad MF, Lillioja S, Nyomba BL, Castillo C, Ferraro R, De Gregorio M, 
Ravussin E, Knowler WC, Bennet PH, Howard BV, Bogardus C: Racial 
differences in the relation between blood pressure and insulin resistance. N Engl 
J Med 1991;324:733-739. 
8. Johnson PR, Greenwood MRC, Horwitz BA, Stern JS: Animal models of 
obesity: Genetic aspects. Ann Rev Nutr 1991;11:325-353. 
9. Stunkard AJ, The body-mass index of twins who have been reared apart. N Engl 
J Med 1990;322:1483-1487. 
10. Bouchard C: The response to longterm overfeeding in identical twins. N Engl J 
Med 1990;322:1477-1482. 
11. Ivy JL, Sherman WM, Cutler CL, Katz AL: Exercise and diet reduce muscle 
insulin resistance in obese Zucker rat. Am J Physiol 1986;251:E299-E305. 
12. Barnard RJ, Ugianskis EJ, Martin DA, Inkeles SB: Role of diet and exercise in 
the management of hyperinsulinemia and associated atherosclerotic risk factors. 
Am J Cardiol 1992;69:440-444. 
13. Weekes TEC, Wable KWJ, Lebaijuri MB: Effects of dietary triolein and 
sunflower oil on insulin release and lipid metabolism in Zucker rats. Lipids 
1986;21:220-225. 
6 
14. Berke BM, Kaplan ML: Effects of high fat and high carbohydrate diets on 
development of hepatic and adipose lipogenesis in fa/fa and non fa/fa rats. J 
Nutr 1983; 1 13:820-834. 
15. Shillabeer G, Homford J, Forden JM, Wong NCW, Lau DCW: Hepatic and 
adipose tissue lipogenic enzyme mRNA levels are suppressed by high fat diets in 
the rat. J Lipid Res 1990;3 1:623-631. 
16. Shillabeer, G, Homford J, Forden JM, Wong NCW, Russell JC, Lau DCW: 
Fatty acid synthase and adipsin mRNA levels in obese and lean JCR:LAcp: effect 
of diet. J Lipid Res 1992;33:31-39. 
17. Grimditch GK, Barnard RJ, Hendricks L, Weitzman D: Peripheral insulin 
sensitivity as modified by diet and exercise training. Am J Clin Nutr 1988;48:38-
43. 
18. Pedersen 0, Kahn· CR, Flier JS, Kahn BB: High fat feeding causes insulin 
resistance and a marked decrease in the expression of glucose transporters (Glut 
4) in fat cells of rats. Endocrinology 1991;129:771-777. 
19. Marshall JA, Shetterly S, Hoag S, Hamman RF: Dietary fat predicts conversion 
from impaired glucose tolerance to NIDDM. Diabetes Care 1994;17:50-56. 
20. Barnard RJ, Faria DJ, Menges JE, Martin DA: Effects of a high-fat, sucrose diet 
on serum insulin and related atherosclerotic risk factors in rats. Atherosclerosis 
1993;100:229-236. 
21. Mufunda J, Chimoskey JE, Matenga J, Musabayane C, Sparks HV: Blood 
pressure responses to acute changes in dietary sodium in young Zimbabwean 
men. J Hypertens 1991; 10:279-285. 
22. Hall JE, Coleman TN, Mizelle HL: Does chronic hyperinsulinemia cause 
hypertension. Am J Hypertens 1989; 2: 171- 173. 
23. Brands MW, Mizelle HL, Gaillard CA, Hilldebrandt DA, Hall JE: The 
hemodynamic response to chronic hyperinsulinemia in conscious dogs. Am J 
Hypertens 1991; 4:164-168. 
24. Creager MA, Liang CS, Coffman JD: Beta adrenergic-mediated vasodilator 
response to insulin in the human forearm. J Pharm Exp Ther 1985; 235:709-714. 
25. Anderson EA, Hoffman RP, Balon TW, Sinkey CA, Mark AL: Hyperinsulinemia 
produces both sympathetic neural activation and vasodilation in normal humans. 
J Clin Invest 1991; 87:2246-2252. 
26. Anderson EA, Balor TW, Hoffman RP, Sinkey CA, Mark AL: Insulin increases 
sympathetic activity but not blood pressure in borderline hypertensive humans. 
Hypertension 1992; 19:621-627. 
7 
27. Neahring JM, Meier T, Hoffman RG, Egan BM: Insulin does not antagonize 
forearm vascular alpha-adrenergic reactivity in man . Am J Hypertens 1992; 
5:17A. 
28. Som.Iyo AP, Somlyo AV: Signal transduction and regulation in smooth muscle. 
Nature 1994; 372:231-236. 
29 . Levy J, Zemel MB, Sowers JR: Role of cellular calcium in abnormal glucose 
metabolism and diabetic hypertension. Am J Med 1989;87(6A):7S-16S. 
3 0. Bell B: Molecular defects in diabetes mellitus. Diabetes 1991;4 0:413-422. 
31. Sowers JR, Khoury S, Standley P, Zemel P, Zemel M: Mechanisms of 
hypertension in diabetes. Am J Hypertens 1991;4:177-182 .  
32. Zemel MB, Johnson BA, Ambrozy SA. Insulin-stimulated vascular relaxation. 
Role of Ca2+-ATPase. Am J Hypertens 1992;5:637-641. 
33. Kahn AM, Ayyar M, Allen JC, Seidel CL, Shelat H, Song T: Physiological insulin 
concentrations inhibit agonist-stimulated contraction of cultured canine femoral 
artery vascular smooth muscle cells . FASEB J 1992;6:A1543. 
34. Barbar DA, Tackett RL: Insulin accentuates vasoconstrictor responses to 
phenylephrine by a mechanism dependent on protein synthesis . Circ Res 1992; 
35. Baron AD, Brechtel G: Insulin differentially regulates systemic and skeletal 
muscle vascular resistance . Am J Physiol 1993;265:E61-E67. 
36 . Dodson PM, Horton RC: The hypertension of diabetes mellitus: mechanisms 
and implications. J Human Hypertens 1988;1:241-247 . 
37 . Standley PR, Bakir MH, Sowers JR. Vascular insulin abnormalities, 
hypertension, and accelerated atherosclerosis. Am J Kidney Dis 1993;21:39-46. 
38. Sowers JR, Standley PR, Ram JL, Zemel MB, Resnick LM. Insulin resistance, 
carbohydrate metabolism, and hypertension . Am J Hypertens 1991;4:466S-472S . 
8 
PART 2 
LITERATURE REVIEW 
9 
I. VASCUIAR TONE AND TOTAL PERIPHERAL RESISTANCE IN 
HYPERTENSIVE STATES 
Blood flows through the body carrying oxygen and nutrients to the tissues and 
carbon dioxide and wastes away from the tissues. For tissues to remain healthy, a fairly 
constant rate of blood flow must be maintained. According to Ohm's law: 
Q = pressure difference 
resistance 
the rate of flow (Q) through any conduit is determined by the driving force (pressure 
difference) behind the fluid inside the conduit and the hindrance (resistance) to flow 
resulting from the friction of moving molecules against each other and the walls of the 
conduit. The length and radii of the conduits of a system and the viscosity of the fluid 
moving through the system are the three factors which influence resistance ( 1 ). The 
circulation is a closed circuit of conduits containing arteries, arterioles, capillaries, 
venules, and veins. The sum of the resistances of all systemic blood vessels is the total 
peripheral resistance. At a constant blood pressure, if the total peripheral resistance 
increases, then blood flow to the tissues will decrease. Therefore, compensatory 
increases in blood pressure must accompany increases in total peripheral resistance to 
maintain a constant rate of blood flow and thus homeostasis at the tissue level (2). 
There are many factors which regulate the total peripheral resistance exerted by 
the circulatory system and manage to keep it at a level of pressure and flow which is 
satisfactory for tissue gas and chemical exchange. However, when regulation is 
dysfunctional and total peripheral resistance increases, arterial pressure must rise to 
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maintain tissue blood flow. The consequence of this compensatory mechanism is the 
disease state, hypertension (1). 
A. Determinants of total peripheral resistance 
From a purely physical perspective, the total peripheral resistance is determined 
by blood viscosity, length and ramification of the vasculature and most importantly, the 
vessel radii (2). The viscosity of blood in the average human being is determined 
primarily by the hematocrit, or proportion of red blood cells in the blood. Red blood 
cells typically comprise about 40% of the blood volume. In polycythemia ( as occurs at 
high altitudes) and anemia ( accompanying some nutrient deficiencies) the red blood cell 
concentration rises and falls, respectively and may significantly affect the resistance to 
blood flow. These conditions are typically acute, treatable and do not contribute to the 
pathogenesis of hypertension in the general population (3). 
The length and ramification of the circulatory system is, at any given time, 
constant. Acute changes in this component are not under consideration in altering 
resistance, however angiogenesis does occur over the long term in some organisms for 
various reasons. When angiogenesis does occur, for instance with increased adiposity, 
capillary density is rarefied and vascular resistance appears to increase ( 4, 5). 
The radii of the vessels of the circulatory system are not constant. Vessels 
undergo both acute changes in diameter ( constriction and dilation) and long term 
changes in diameter ( atherosclerotic lesions). Small decreases in the radii of resistance . 
vessels, produce large changes in resistance because, according to Poiseuille's Law and 
the concept of laminar flow, resistance is inversely proportional to the fourth power of 
the radius (2, 6). Although larger arteries and veins contract and dilate to some extent, 
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the major site of regulation of total peripheral resistance in the systemic circulation is at 
the arteriole and metarteriole. The state of constriction and relaxation of the smooth 
muscle of these vessels found embedded within tissues is largely the determinant of total 
peripheral resistance. In addition, constriction or relaxation of selective arterioles 
controls resistance and thus pressure and blood flow to the tissue or organ the arteriole 
feeds (7). Therefore, when one tissue bed has increased resistance, another must have 
decreased resistance if arterial pressure is to remain constant ( 1 ). 
B. Regulation of vascular resistance 
The major regulating mechanism for vascular resistance is vessel diameter control 
(2). Small arteries and arterioles are innervated by the sympathetic nervous system 
originating at the vasomotor center in the medulla. There is constant tonic stimulus of 
contraction of the smooth muscle of the vasculature. Increased sympathetic nervous 
activity will result in increased constriction while reduced sympathetic input will result in 
dilation (8). 
Another regulator of vessel diameter, intrinsic or myogenic tone in smooth 
muscle, in some small arteries and arterioles has been shown to exist independent of 
innervation or circulating factors. Cells simply depolarize and contract in response to 
increased intravascular pressure. The mechanism of this response is unknown, but 
activation of specific potassium channels (possibly by simple mechanical stretch due to 
pressure) that cause depolarization and calcium influx is suspected (9, 10). 
Furthermore, there are numerous chemical regulators of vascular tone. 
Hormones, such as vasopressin, angiotensin II and epinephrine are circulating 
vasoconstrictors that bind to membrane receptors and, acting through cellular second 
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messengers, elicit excitation-contraction coupling in smooth muscle cells. Other 
circulating hormones, such as atrial natriuretic peptide act by similar pathways but result 
in relaxation and vasodilation (1 1). 
Other chemical substances, such as arachidonate or prostaglandins, act in a 
paracrine or autocrine fashion and may result in contraction or relaxation by acting on 
membrane proteins and eliciting signal transduction ( 1 1  ). In addition, excessive 
metabolic end products or substrates ( carbon dioxide and oxygen) in surrounding tissues 
may have a tremendous local effect on arteriolar radii and thus resistance. Hypoxic 
tissues vasodilate in an attempt to increase blood flow and thus oxygen delivery. These 
effects may be direct or due to vasodilator substances released from compromised tissues 
( 11). 
C. Derangements of vascular tone and total peripheral resistance in hypertension 
The blood flow rate ( cardiac output) is equal to the mean arterial pressure 
divided by the total peripheral resistance. Therefore, if either total peripheral resistance 
or cardiac output increases the arterial blood pressure increases as well ( 1 ). 
Cardiac output (blood flow rate from the heart) equals the stroke volume times 
the heart rate. Heart rate is controlled primarily by an intrinsic rate from the sinoatrial 
node with further input from the autonomic nervous system, through the 
cardioacceleratory and inhibitory centers of the medulla. Mild tachycardia, in exercise 
for example, may contribute to an increased cardiac output and blood pressure, but 
excessive tachycardia may decrease cardiac output because there is little time for 
ventricular filling between beats and stroke volume is compromised (12). 
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Stroke volume is dependent on venous return, nervous influence on contractility, 
and the structural capabilities of a given heart. As reflected in the Frank-Starling 
mechanism, the heart has the intrinsic capability to pump, within physiological limits, the 
incoming blood from the venous system. Regardless of the afterload ( aortic pressure) 
the cardiac output is dependent on the preload (end-diastolic volume) (13). 
Some investigators suggest that increases in the total peripheral resistance are 
immediately corrected by properly functioning kidneys and thus do not lead to long term 
increases in blood pressure. Increased renal blood pressure results in pressure 
natriuresis and diuresis with subsequent decreases in blood volume and thus venous 
return (1). Others maintain that decreasing the extracellular volume with 
pharmacological agents ( diuretic therapy) does not lower hypertension adequately in 
every individual, while those drugs which decrease total peripheral resistance (Ca2+ 
channel blockers, angiotensin converting enzyme inhibitors, and alpha-receptor 
antagonists) may (14). Laragh and others maintain that hypertension is clinically and 
endocrinologically heterogenous, and thus requires individualized pharmacological 
intervention. However, the common factor in all diastolic hypertensive states is 
vasoconstriction which may be renin-angiotensin-mediated (high renin) or sodium­
volume-rela ted (low renin) (15). 
Cellular calcium abnormalities may occur in both low and high renin hypertensive 
states. In the low-renin type, abnormal calcium regulation between intracellular and 
extracellular sites may result in increased dependence of blood pressure on extracellular 
calcium and enhanced sensitivity to calcium channel blockers (16). In contrast, high­
renin hypertensives exhibit reduced sensitivity to therapeutic treatment with calcium 
channel blockers, and thus calcium dysregulation occurs between the cytosol and 
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intracellular storage sites ( 16). Regardless, in both cases increases in intracellular 
calcium may lead to increased vasoconstriction and consequent increases in total 
peripheral resistance ( 1 1  ). 
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II. CELL CALCIUM AND EXCITATION-CONTRACTION COUPLING IN 
VASCULAR SMOOTH MUSCLE 
There are many determinants of vascular smooth muscle tone. Among these, 
stretch of smooth muscle cells opens ionic channels, as does voltage changes on the 
extracellular surface. In addition, multiple chemical substances and hormones such as 
norepinephrine, angiotensin II and vasopressin act on cell surface receptors to cause 
entry of ions through specific channels or release of ions from intracellular stores. 
Numerous other proteins are undoubtedly involved in modulating the sensitivity to ion 
concentrations, although these mechanisms are not clearly understood (11). 
A. Excitation contraction coupling 
The excitation-contraction mechanism in smooth muscle is very different than 
that in skeletal or cardiac muscle. In smooth muscle increased intracellular calcium 
binds to calmodulin and, together, these activate a myosin light chain kinase which 
phosphorylates the myosin light chains in the contractile apparatus. Both heads of the 
myosin molecule must be phosphorylated for the molecule to have Mg2+ -A TPase activity. 
Phosphorylation of the myosin light chains apparently increases the flexibility of the 
myosin-actin junction allowing for actin-activated Mg2+ -A TPase activity. Cleavage of 
high energy phosphate bonds of the ATP allows contraction to occu_r. The myosin heads 
may then be dephosphorylated by a protein phosphatase. Thus, increases in cytosolic 
calcium, activation of myosin light chain kinase, phosphorylation of myosin, followed by 
interaction with actin, results in production of force and shortening. Conversely, 
decreases in cytosolic calcium and dephosphorylation produce relaxation (17). 
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Like other muscle types, vascular smooth muscle contraction is a calcium­
dependent cellular event ( 1 1  ). However, the status of intracellular calcium is not the 
only determinant of contractile activity. Although poorly understood, there are many 
interactions between the thick ( myosin) and thin ( actin, tropomyosin, caldesmon and 
calponin) filament proteins and sarcoplasmic protein kinases and phosphatases. (18) 
Some of these proteins are suspected to modulate the sensitivity of the contractile 
apparatus to calcium by phosphorylation events. For instance, protein kinase C (which is 
activated by diacylglycerol in the phosphoinositol second messenger system) 
phosphorylates a site on the myosin light chain kinase causing a lowered affinity for 
calcium-calmodulin molecules and a resultant decrease in myosin light chain 
phosphorylation ( 18). 
B. Calcium concentrations in the body fluids 
Calcium is an essential ion in excitable cells, in addition to its second messenger 
actions in all cells. Therefore, the concentration gradients of calcium between extra- and 
intracellular spaces are tightly controlled by homeostatic mechanisms. Hypocalcemia 
results in tetany, while hypercalcemia results in lethargy, diuresis, arterial hypertension, 
and other serious symptoms, each of which can lead to death. Three main calcitrophic 
hormones which control the concentration of calcium are parathyroid hormone, calcitriol 
and calcitonin (19). 
Parathyroid hormone is released from the parathyroid gland and acts, via cAMP, 
primarily on the bone and kidney; the primary stimulus for its release is decreased 
ionized calcium in plasma (20). In bone, parathyroid hormone stimulates osteoclast 
activity causing demineralization and release of calcium into the plasma. In the kidney, 
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parathyroid hormone activates 1-alpha-hydroxylase which hydroxylates carbon 25 of 
calcidol ( 1-0H-D3) to form calcitriol ( l,25-(0H)i-D3) in the proximal tubule. It also 
stimulates phosphodiuresis and favors the reabsorption of calcium (20). 
Calcitriol is a metabolite of Vitamin D3 which acts as a steroid hormone on the 
intestinal cells to increase calcium binding protein synthesis and thus calcium absorption. 
It also has a permissive effect with parathyroid hormone in bone. The combined actions 
of calcitriol and parathyroid hormone result in increased calcemia (21). 
In contrast, calcitonin is produced and released by the parafollicular C cells of the 
thyroid when plasma calcium levels increase above normal. It acts, via cAMP, to inhibit 
osteoclast activity in bone and to increase calcium excretion in the kidneys. Several 
gastrointestinal hormone stimulate secretion of calcitonin. Maintenance of extracellular 
calcium levels by the aforementioned hormones is critical to the function of excitable 
cells (22). 
Levels of these circulating endocrine factors are altered in some forms of 
hypertension. Parathyroid hormone levels are increased in low-renin, salt sensitive 
humans and animals (19). Calcitrioi in excess, appears to increase intracellular calcium 
and exert a pressor effect in low-renin hypertensives, as well. Thus, therapeutic efforts 
for increasing plasma calcium and reducing the circulating levels ( dietary calcium 
supplementation) of these hormones are suitable for some patients (19). Again, the 
major factor determining vascular smooth muscle contraction is intracellular calcium 
levels, and the effects of calcium regulatory hormones on intracellular calcium levels are 
less clear than the effects on extracellular concentrations. 
Cytosolic calcium concentrations in vascular smooth muscle and other cells are 
maintained within a rather narrow range around 10-7 M. Extracellular calcium 
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concentrations are approximately 10-3 M, while intracellular compartmentalized calcium 
concentrations are approximately 10-5 M. Therefore, there are concentration gradients 
from outside to inside the cell and from intracellular compartments to the cytosol (23). 
The three major components to be considered in myoplasmic regulation of cell calcium 
are calcium influx, extrusion and sequestration (24 ); and these will be discussed in detail 
below. 
C. Mechanisms of calcium influx 
Calcium entry in vascular smooth muscle has been studied both by measuring the 
ionic flux of the isotope 45Ca and by patch clamp techniques. Calcium enters the 
vascular smooth muscle cell cytosol from the extracellular space by four distinct 
mechanisms. The leak pathway, voltage-gated channels, stretch sensitive (myogenic) and 
hormone-receptor operated channels are present on the plasmalemmal membrane. 
There are distinct differences in calcium channels in vascular smooth muscle cells 
compared to those in cardiac muscle cells (25). 
Passive leak of calcium occurs in a unidirectional mode in the absence of 
depolarization, stretch or agonist stimulation. The channels responsible for this leak 
have not been clearly identified, but are blocked by increasing hydrogen ion 
concentrations or polyvalent cation addition. The leak of calcium into the cytosol is 
compensated by constant sequestration and extrusion so that intracellular calcium 
concentrations remain fairly stable, however, if these homeostatic mechanisms are 
altered, leak may play a role in smooth muscle activation (26). 
The voltage-gated channels, which are the best understood, are members of a 
gene super family which includes voltage dependent sodium and potassium channels and 
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are inhibited with dihydropyridines and augmented by Bay K8644 (25). There appear to 
be distinct types of these channels in different muscle tissues; most are activated by 
potassium depolarization and are dependent on extracellular calcium. There is a slow, 
sustained, high threshold or L type current (plasma membrane dihydropyridine receptor) 
which is distinguished from a fast, transient, low threshold or T type current (25, 27). 
The evidence suggests increased activity in L type channels in hypertensive animals (27). 
Activation of stretch sensitive channels may be dependent on the presence of 
endothelium, suggesting some intermediary substance. These are sensitive to diltiazem 
but not dihydropyridines. Receptor operated channels appear to be directly operated by 
ATP and are insensitive to dihydropyridines (11). 
Calcium can also enter the cytosol through second-messenger-operated channels 
present on the sarcoplasmic reticulum membrane. The first channel is an inositol 
triphosphate (IP 3) receptor-operated channel and is inhibited by heparin (25) and may 
be modulated by calcium itself (26, 28). It requires the presence of guanosine 
triphosphate and is therefore thought to be activated through a guanosine triphosphate­
binding protein (29). The ryanodine receptor, another intracellular release calcium 
channel, is found in smooth muscle in much lower levels than in striated muscle (25). 
The mode of activation for this receptor is unknown; however it does appear to be 
involved in calcium-stimulated calcium release (11, 26) and modulated by cADPr (28). 
D. Mechanisms of calcium efflux and seguestration 
Calcium is extruded from vascular smooth muscle cell cytosol to the external 
environment or internal compartments via active transport. Two distinct Ca2+  -A TPases 
exist on the plasmalemmal and sarcoplasmic reticulum membranes. In addition, calcium 
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is extruded from the cell by a Na+ -coupled exchanger on the plasma membrane a 
mitochondrial pump-leak activity of calcium (26). 
Metabolic inhibition of smooth muscle is accompanied by increases in cytosolic 
calcium, as the major source of calcium efflux is a plasma membrane ea2+ -A TPase. It is 
a 130 kilodalton protein which is stimulated by calmodulin and inhibited by vanadate. 
Unlike the Na+-K+-ATPase this pump is insensitive to ouabain. It is suspected that 
prostaglandins and oxytocin inhibit the activity of this pump, and thereby cause 
contraction (30). The mRNA of this pump is increased with treatment of smooth muscle 
cells with insulin (31 ). 
Although the plasmalemmal Na+ -ea2+ -exchanger has not yet been purified it is 
an antiport known to be dependent on Na+ and Ca2+ gradients and membrane potential. 
The stoichiometry of the pump is 3Na+ :ea2+ in and out, respectively. Under 
physiological conditions this pump does not appear to be critically involved in calcium 
homeostasis; however, in hypertensive states it may become more important (33). 
The sarcoplasmic reticulum Ca2+ -A TPase is a 100 kilodalton protein with 2 
isoforms ( 11 ). The calcium storage capacity of the sarcoplasmic reticulum is enhanced 
by the calcium-binding proteins calsequestrin and calreticulin which are found on the 
luminal surface. Agents which inhibit the plasmamembrane Ca2+ -A TPase, such as 
cyclopiazonic acid and thapsigargin, and thereby lead to the depletion of intracellular 
stores, cause an increase in calcium influx from the plasmamembrane. The mechanism 
for this influx has not been identified, but appears to require GTP hydrolysis and some 
intracellular message which may be sequestered with calcium in a given compartment 
(28). 
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Calcium influx, efflux and sequestration may be influenced by a myriad of 
extracellular and intracellular substances, such as insulin. These factors may control the 
transcriptional or translational expression, activity and turnover of calcium regulating 
proteins and thus the contractile state of the cells. 
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ill. RELATIONSHIPS AMONG OBESITY, INSULIN RESISTANCE 
AND HYPERTENSION: SYNDROME X 
Obesity, insulin resistance and hypertension occur together more than individually 
in the general population. This is so much so that Reaven, in 1988, described a 
syndrome which he called "X" and included the following pathological conditions: 
dyslipidemia, hyperinsulinemia and hypertension (33, 34). Kaplan subsequently observed 
that android shaped obesity, characterized by increased visceral fat and androgen levels, 
was also frequently present along with these risk factors for cardiovascular disease. He 
termed these clustered symptoms "the deadly quartet": upper-body obesity, glucose 
intolerance, hyperlipidemia and hypertension (35). 
The aforementioned risk factors of cardiovascular disease do not always occur 
together, but in various combinations (36 - 56). Thus, hypertension is part of a 
syndrome which includes abnormalities of carbohydrate and lipid metabolism and insulin 
sensitivity, sometimes independent of obesity (36, 38, 39). Several studies have shown 
that insulin-mediated glucose disposal is significantly reduced in both nonobese and 
obese subjects diagnosed with hypertension when compared to controls (36 - 38). In 
addition, basal insulin, total cholesteroL triglycerides and free fatty acids are significantly 
increased in both obese and nonobese hypertensives (36). Moreover, hyperinsulinemic 
euglycemic clamp studies demonstrate significant blood pressure elevations in individuals 
with reduced insulin sensitivity (37). Thus, insulin resistance, independent of obesity, is 
associated with hypertension. 
Insulin resistance, with compensatory hyperinsulinemia, has been said to be the 
factor which links obesity and hypertension (33 - 36, 42 - 46, 49, 53, 56). Indeed, 
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individuals with diagnosed non-insulin-dependent diabetes (NIDDM) are frequently 
obese and hypertensive (35). The major cause of morbidity and mortality from NIDDM 
is coronary artery disease (CAD). The etiology of CAD associated with NIDDM is the 
focus of research in many physiology and nutrition laboratories. The perturbations 
present when insulin is absent or target tissues are resistant to insulin effects include 
acidosis, arteriosclerosis and general wasting (33 - 35). Therefore, it is important to 
understand the growth promoting and metabolic actions of insulin in the normal 
individual in comparison to those in pathological insulin states. 
A. Insulin signal transduction 
The insulin gene is located on the short arm of chromosome 11 in humans, 
encoding 3 exons with a total of 1430 base pairs ( 57). The biologically active insulin 
molecule consists of two polypeptide chains connected by two disulfide bridges. It is 
produced from a high molecular weight precursor, preproinsulin, and processed in the 
rough endoplasmic reticulum of pancreatic Ji cells (58). Proteolytic cleavage results in 
equimolar quantities of insulin and C ( connecting) peptide. The bridged portion of the 
molecule is conserved, but the other amino acids vary considerably among different 
species. Circulating glucose is the major stimulus for the apparently independent 
processes of insulin synthesis and secretion (59). 
The 120 kilobase insulin receptor gene is located on human chromosome 19 and 
contains coding regions for an « and Ji subunit as well as a signal sequence (60). The 
promoter region is GC-rich and lacks TATA or CAAT boxes. Three transcriptional 
activation sites have been identified and contain putative transcriptional activator Sp 1 
binding regions ( 61 ). Transcription of the insulin receptor is upregulated in part by a 
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glucocorticoid response element in the 5'-flanking region, and interestingly, there is a 
reciprocal insulin responsive element on the glucocorticoid receptor ( 62). Proteolytic 
processing of a 1382 preproreceptor results in a 731 amino acid a. subunit which is 
external to the plasma membrane, and a 620 amino acid p subunit with 194 extracellular 
amino acids, 23 spanning segment amino acids and 403 cytoplasmic domain amino acids. 
Two a. and two P subunits form disulfide linked heterotetramers which are glycosylated 
on the extracellular side. The cytoplasmic domain has tyrosine kinase activity and is thus 
the proposed "first step" in the insulin signalling cascade described below (61). 
The insulin signal transduction pathway is not yet clearly defined. The multiple 
cellular actions of insulin in various tissues make it unlikely that there is simply one 
pathway or mechanism of action (62). The insulin receptor belongs to a family of 
tyrosine kinases which transfer the gamma phosphate of ATP to tyrosine residues on 
other proteins or autophosphorylate (63). Insulin simultaneously increases the 
phosphorylation of some proteins ( ribosomal S6, ATP citrate lyase, calmodulin) and the 
dephosphorylation (glycogen synthase, pyruvate dehydrogenase, hormone-sensitive lipase, 
Glut4) of others. The protein phosphatase inhibitor okadaic acid inhibits many of the 
actions of insulin, yet potentiates insulin-stimulated glucose transport (64). 
It is thus proposed that the tyrosine kinase activity initiated by insulin binding to the 
insulin receptor is the first step in a phosphorylation cascade that has the potential of 
affecting numerous cellular proteins (65). 
Immediately following a meal, the blood glucose rises and is the main stimulus 
for the rapid secretion of insulin. Amino acids and gastrointestinal hormones potentiate 
the release of insulin to a glucose stimulus. Insulin release is a biphasic phenomenon, 
with preformed, stored insulin released immediately and a sustained release of freshly 
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synthesized insulin secreted within an hour. Insulin circulates unbound with a plasma 
half-life of 6 minutes and is destroyed by insulinase in the liver or kidneys (66). Steroid 
hormones, such as cortisol, progesterone and estrogen increase insulin production and 
may, in large prolonged doses, result in p cell overuse and malfunction. Growth 
hormone has an effect on insulin metabolism as well, possibly related to insulin-like 
growth factor I (IGF-1) cross reactivity with the insulin receptor (67). 
B. Classical actions of insulin 
Since its discovery and extraction from the pancreas by Banting and Best in 1922, 
insulin has been known primarily for its effects on metabolism (68). Insulin action has 
historically been considered pathway specific and tissue specific. Lipogenesis, 
glycogenesis and glucose utilization are among the traditional metabolic pathways that 
insulin, in concert with other chemical substances, regulates. The traditionally accepted 
target tissues of insulin are adipose, liver and skeletal muscle ( 65). 
In adipose tissue, insulin increases amino acid, potassium and glucose uptake (via 
Glut4), lipogenesis (via activation of lipoprotein lipase and fatty acid synthase), and 
protein synthesis. It decreases lipolysis (via inhibition of hormone-sensitive lipase), and 
proteolysis. Indirectly, insulin increases the utilization of glucose as an energy-producing 
substrate for the rest of the body and thus acts as a "fat sparing" hormone. In the 
absence of insulin, an accumulation of fatty acids in the plasma res11:lts in shifting 
utilization of other metabolic substrates to ketone bodies. In addition, the absence of 
insulin's combined actions with the liver results in increased plasma lipoprotein 
concentrations (66). 
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In striated muscle insulin also increases amino acid, potassium and glucose 
uptake (via Glut4) and protein synthesis. In addition, it stimulates glycogen synthesis 
and inhibits proteolysis ( 66). 
In the hepatocytes, insulin increases potassium uptake, glycogen, protein and fatty 
acid synthesis and inhibits glycogenolysis, gluconeogenesis and proteolysis. In contrast to 
adipose tissue and skeletal muscle, insulin does not directly stimulate glucose transport in 
hepatocytes. Instead there is an indirect increase in glucose transport as a result of 
insulin activation of glucokinase, the enzyme responsible for phosphorylation and 
temporary trapping of glucose in the cell. Insulin also inhibits phosphorylase and 
stimulates phosphofructokinase and glycogen synthase, resulting in hepatic glucose 
storage in the postabsorptive state (66). 
The overall widely accepted actions of insulin are present in the absorptive state 
and lead to anabolism and storage of metabolic substrates for later periods of 
macronutrient deprivation. Glucagon is the counter hormone secreted by the pancreas, 
during fasting, and affects the liver with actions which oppose those of insulin. 
C. Non-classical actions of insulin 
In recent years, recognition of insulin's actions on cellular activities, other than 
metabolic substrate regulation, has led to a different view of the hormone. Insulin is 
now regarded as a growth factor which contributes to the normal growth and maturation 
process ( 68). Insulin modulates the production of lipogenic and glycolytic enzymes, as 
well as structural cellular proteins, possibly via protein phosphorylation cascades (65). In 
addition, regulation of intracellular calcium, and other ions, through transcriptional 
control of membrane ATPases appears to be one of insulin's important roles (69, 70). 
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D. Theories of insulin association with hn,ertension 
Hypertension in insulin resistant states has generally been attributed to a 
compensatory increase in circulating insulin ( 55). The obsetved hyperinsulinemia may be 
due to increased pancreatic secretion of insulin, due to lack of negative feedback as 
result of failure to lower blood glucose (55, 71). Another explanation for 
hyperinsulinemia is impaired hepatic extraction, not pancreatic secretion, as fasting C­
peptide levels are comparable in nonhypertensive versus hypertensive NIDDM subjects, 
while insulin is up to 70% higher in hypertensives (71, 72). Excess insulin has been 
shown to increase sympathetic nerve activity and renal sodium reabsorption, both of 
which may lead to hypertension. However, many of these effects of insulin have been 
demonstrated with supraphysiological doses that do not reflect the plasma insulin status 
of hyperinsulinemic individuals (73). In contrast, recent evidence suggests that insulin 
elicits a direct vasodilatory response from the vasculature (74 - 79) which is due, in part, 
to insulin regulation of calcium regulatory proteins (31, 80 - 91). 
1. Hyperinsulinemia and sympathetic activation 
Hyperinsulinemia, with or without obesity, has been associated with hypertension 
in several studies (33 - 36, 42 - 46, 49, 53, 56, 73, 92 - 97). While metabolic responses to 
insulin in target tissues are abnormal in insulin resistant states, it appears that insulin 
sensitivity of the sympathetic nervous system remains intact (98). l;"here appears to be a 
fundamental relationship between macronutrient intake and sympathetic activity (93). 
Fasting and caloric restriction have been shown to suppress sympathetic activity in a 
number of tissues, such as heart and brown adipose tissue, while overfeeding stimulates 
sympathetic activity (93). Insulin-mediated glucose metabolism in central neurons within 
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the ventromedial hypothalamus is implicated in this phenomenon, as hypoglycemia, 2-
deoxyglucose, and streptozotocin-induced diabetes lowers sympathetic activity. 
Moreover, plasma norepinephrine levels are increased with euglycemic insulin infusion in 
normal humans (96). 
Although many studies have shown that hyperinsulinemia increases sympathetic 
nerve activity (92 - 97) other have not (99). Insulin injection into the hypothalamus 
actually decreases sympathetic nerve firing rate (99). Furthermore, few studies have 
found insulin to raise blood pressure when infused in normal persons or animals (73), 
although insulin infusion has been shown to increase blood pressure in some rat strains 
(97). Conversely, high blood pressures are sustained under ganglionic blockade in 
hyperinsulinemic, insulin resistant Zucker obese rats (100). 
In normal humans, insulin infusion has been shown to exert a vasodilatory effect 
with decreases in vascular resistance and blood pressure (74, 76 - 77). It has been 
su�ested then that hyperinsulinemia may only cause increases in blood pressure in 
insulin resistant subjects, due to selective tissue resistance. In other words, the 
vasodilatory actions of insulin are resistant, while the kidney and sympathetic nervous 
system remain responsive (73). In support of this notion, insulin increases skeletal 
muscle blood flow and decreases local vascular resistance more than it increases systemic 
vascular resistance; these effects are blunted in obesity. 
The paradoxical results of insulin effects on sympathetic activity and blood 
pressure may represent species differences (73), as well as environmental versus genetic 
etiology (93). It is clear that insulin increases circulating catecholamines in many species 
(93). However, the role of hyperinsulinemia and insulin activation of sympathetic nerves 
in hypertension has not been established. It is possible that impairment of insulin's 
29 
vasodilatory actions in insulin resistance may be permissive to insulin's stimulation of 
sympathetic activity. 
2. Renal Sodium Retention 
Insulin has been shown to have an antinatriuretic effect on the kidney in 
nonphysiological concentrations in normal, obese and diabetic individuals (69, 73, 101 -
103). In addition, physiological hyperinsulinemia induced during oral glucose tolerance 
tests results in reduction of sodium excretion in both normo- and hypertensives (101). It 
is not yet clear whether insulin exerts a greater antinatriuretic effect in hypertensives, 
independent of hyperinsulinemia. 
Renal blood flow and glomerular filtration rate remain relatively normal in obese 
hypertensives, but increase during development of obesity-induced dog models of 
hypertension (73). However, there is a parallel shift in the pressure natriuresis curve so 
that sodium balance is achieved at a higher blood pressure (73). The increase in sodium 
and chloride reabsorption appears to be a defect somewhere past the proximal tubule 
(103). Interestingly, plasma renin activity in obese hypertensives and the dog model of 
obesity induced hypertension is elevated, despite a decrease in sodium excretion and 
expansion of the extracellular fluid volume. It has been suggested that the chloride 
concentration at the macula densa is decreased, causing renin release by juxtaglomerular 
cells and thus failure to suppress angiotensin II formation (73, 103 ). If this is the case, 
the sodium and chloride reabsorption must occur in the loop of Henle sections and may 
be related to increased interstitial pressures compressing both the loop and vasa recta, 
thereby slowing tubular flow rate and allowing more time for sodium reabsorption in 
these sections (73 ). 
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The cause of increased sodium reabsorption and a shift in the pressure 
natriuresis in kidneys of obese hypertensives remains unclear. Theoretically, it could be 
altered renal hemodynamics that go unrecognized because the kidney adjusts in the long 
term, tubular resistance to insulin actions, or as Hall et al. sug_gest, a structurally 
mediated decrease in medullary flow rates (73, 103). 
3. Cation transport 
The role of ions in regulating insulin actions, and conversely insulin regulating ion 
transport has been the focus of several recent studies (31, 69, 80 - 91, 104 - 107). 
Inheritance of abnormal calcium regulatory mechanisms presents strong evidence that 
cation transport in at least some hypertensives is a primary problem. Platelets from 
offspring of hypertensives exhibit higher baseline calcium levels than controls. (105) In 
addition, erythrocyte membrane calcium A TPase activity in offspring with hypertension 
in their background is lower (106). 
There is a well documented relationship between blood pressure and ion 
concentration homeostasis of sodium and calcium, as the intracellular concentration of 
both cations is increased in hypertensive subjects (70, 73 ). It is estimated that 50% of 
hypertensives are salt sensitive. Acute administration of insulin increases renal sodium 
reabsorption ( 69). When persons with genetic predisposition for hypertension 
consumed high salt diets, those that developed hypertension had higher platelet calcium 
levels and lower plasma ionized calcium than those that remained normotensive (105). 
The regulation of these ions may be related through the renin-angiotensin system, with 
concurrent alterations of both sodium and calcium excretion (104). There is evidence 
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that suggests that renal handling of calcium is impaired in hypertensives with 
hypercalciuria observed in particular in low renin conditions. (107) 
Zemel and others have reported decreased calcium A TPase and associated 
increases in erythrocyte calcium content in elderly and diabetic hypertensives when 
compared to non-diabetic hypertensives and age matched controls (80, 81, 87). However, 
other ions were not significantly different between groups (81 ). Furthermore, insulin has 
been found to increase 45Ca efflux in aorta from normal rats in a dose-dependent fashion 
(88). In precontracted endothelial-vascular strips, insulin increased the rate of 
relaxation, but not in the presence of a calcium A TPase inhibitor (88). The decrease in 
vascular reactivity of normal tissues with insulin treatment is associated with a decreased 
intracellular calcium responses to various vasoactive agonists. 
In cultured rat vascular smooth muscle cells (A7r5), insulin incubation resulted in 
increased expression of plasma membrane and sarcoplasmic reticulum calcium A TPases 
(31 ). In addition, the rate of recovery to baseline calcium following agonist stimulation 
is markedly increased in insulin treated cells (86, 91). Inhibition of agonist-stimulated 
contraction of primary cultured vascular smooth muscle cells also occurs with exposure to 
physiological doses of insulin (89). 
A series of studies using the insulin resistant obese Zucker rat as a model for 
NIDDM associated with hypertension have further elucidated the role of insulin in 
vascular smooth muscle calcium regulation, vascular reactivity and �lood pressure (83). 
Obese Zucker rats consistently have higher conscious blood pressures than lean controls 
(83, 87). In addition, aortic strips from obese animals exhibit exaggerated vascular 
reactivity to agonists and depolarization compared to strips from lean controls (87). 
Erythrocyte calcium ATPase activity and calcium content are decreased (83) similar to 
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human diabetic hypertensives (81 ). Moreover, 45Ca efflux in aortic vascular smooth 
muscle is significantly reduced in obese versus lean animals (83). Rats made insulin 
deficient with streptozotocin injection also exhibit hypertension during stress. Moreover 
aorta from these animals are more reactive to vasoactive agonists and exhibit delayed 
45Ca efflux (84, 90). 
All in vitro effects of insulin observed in the above studies, and by others, require 
1-2 hours of incubation and are inhibitable by treatment with cyclohexamide, a protein 
synthesis inhibitor (85). This strongly suggests that insulin regulation of intracellular 
calcium is at either the transcriptional or translational level. 
Calcium appears to play some role in the more classical actions of insulin 
signalling as well. Youn et al. observed that subcontractile increases in intracellular 
calcium increased glucose transport in skeletal muscle (108). In contrast, Draznin et al. 
found that large increases in intracellular calcium resulted in decreased glucose transport 
in adipose tissues (109). However, the same group later described a bell-shaped 
relationship of glucose transport with increasing intracellular calcium concentrations. It 
appears that the optimal range for calcium stimulation of transport was 140-370 nM 
( 1 10). 
The relationship of intracellular calcium and insulin signal transduction in glucose 
transport in vascular smooth muscle has been studied in our laboratory. We have 
demonstrated that the insulin responsive glucose-transporter GLUT4, is present and that 
insulin stimulated glucose transport occurs in vascular smooth muscle ( 111 ). In addition, 
data from this laboratory links phosphorylation of glucose and a non-metabolizable 
glucose analogue to insulin regulation of calcium metabolism. Incubation of cells with 
glucose or a phosphorylated analogue in combination with insulin resulted in increased 
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expression of plasma-membrane and sarcoplasmic reticulum calcium A 1Pases, and 
increased extrusion of cytosolic calcium following agonist induced transients. These 
results do not occur in glucose-free media or with an analogue which is merely 
transported into the cell and not phosphorylated ( 112). 
Considering the above evidence, hypertension seen in insulin resistant states may 
result from decreased expression of these calcium pumps. This may lead to an overall 
increase in the concentrations of intracellular calcium in vascular smooth muscle and the 
observation of increased vascular reactivity to vasoactive agents (83 ). 
Other less studied explanations for the associations among obesity, insulin 
resistance and hypertension, have recently been recognized or have not received as much 
attention (4, 5, 73). Rarefaction of the vasculature with increasing tissue mass, as in 
obesity, has been proposed to result in insulin resistance from a prereceptor standpoint 
( 5). Decreased density of tissue feeding vessels results in inadequate perfusion of 
nutrients to the tissues as well as increased total peripheral resistance ( 4, 5). However, 
this theory does not adequately explain the relationship of insulin resistance and 
hypertension when obesity is not present. 
E. Pharmacological evidence 
There is quite a bit of pharmacological evidence that insulin resistance and 
hypertension are related, and that calcium is involved, but cause and effect remain 
unclear ( 1 13 - 1 19). It is quite a challenge to treat the diabetic hypertensive, as many 
older hypertensive medications have diabetogenic effects ( 1 13). Thiazide diuretics, 
commonly used in volume expanded hypertensives, increase blood glucose and 
cholesterol. In addition, they decrease potassium and may increase the incidence of 
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impotence, although no direct relation to coronary heart disease has been demonstrated. 
Beta-blockers, used to attenuate sympathetic responses, increase blood glucose and 
inhibit the catecholamine adjustments to insulin-induced hypoglycemia. They also may 
impair responses to hypoglycemic drugs and have been reported to have adverse effects 
on limb blood flow. Another widely used antihypertensive therapy, angiotensin 
converting enzyme inhibition does not appear to be diabetogenic and may actually result 
in increased insulin sensitivity ( 113 ). 
Interestingly, the calcium channel blockers have antidiabetic effects. Nitrendipine 
has been shown to increase 2-deoxyglucose in adipocytes from elderly obese 
hypertensives (114) and diltiazem has been shown to increase insulin receptor tyrosine 
kinase activity (115). Furthermore, glucose-induced insulin secretion is calcium 
dependent, while liver mobilization of glucose is also calcium dependent (glycogenolysis 
and gluconeogenesis ), so these drugs may reduce hyperinsulinemia and hyperglycemia 
along with blood pressure when used by diabetic hypertensives (116). 
Conversely, some antidiabetic drugs studied produce decreases in blood pressure. 
Thiazoledinedione compounds, such as pioglitazone or ciglitazone have produced 
attenuation of blood pressure in Dahl salt sensitive, 1-kidney, 1-clip hypertensive rats and 
Zucker obese rats (117, 1 18). In addition, in cultured vascular smooth muscle cells, 
ciglitazone attenuated sustained platelet-derived growth factor stimulated increases in 
intracellular free calcium (118). Metformin a biguanide which incr�ases insulin 
sensitivity, reduced blood pressure in nondiabetic lean hypertensives (119) and 
spontaneously hypertensive rats (120). 
Thus pharmacological evidence from antihypertensive and antidiabetic 
medications strongly suggests a link between altered insulin states and hypertension 
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( 1 13 - 120). In some studies, calcium is clearly involved in this relationship ( 1 14 - 1 16, 
1 18). The effects of anti-obesity agents, such as f enfluramine, on blood pressure, insulin 
sensitivity and calcium regulation have not been widely studied. 
F. Experimental models of obesity, insulin resistance and hn,ertension 
In most models of experimental hypertension there is an obvious insult to the 
kidney affecting renal blood flow or tubular absorption (73). Compensatory changes in 
blood pressure result in kidney vital functions appearing normal, while cardiac and 
vascular abnormalities become exaggerated. Moreover, in many models of genetic or 
experimentally-induced hypertension, the hypertension follows the kidney in cross­
transplantation studies. Thus transplantation of kidneys from a spontaneously 
hypertensive rat to a normotensive rat results in hypertension in the normotensive rat. 
Conversely, transplantation of kidneys from a normotensive rat to a spontaneously 
hypertensive rat results in normalization of blood pressure ( 121 ). These experiments 
support the kidney as the primary organ responsible for long term blood pressure 
control. Many of these experimental models exhibit other metabolic abnormalities 
related to impaired kidney function and to compensatory circulatory changes. However, 
they do not exhibit obesity or hyperinsulinemia and are thus inadequate models for the 
study of Syndrome X. 
There are fewer models of experimentally induced obesity. Lesions of certain 
areas of the brain, such as the ventromedial hypothalamus, in the rat produce 
hyperphagia and obesity accompanied by hyperinsulinemia ( 122). This mechanism of 
obesity induction was shown to be dependent on neural pathways to the pancreas, 
suggesting autonomic nervous system and insulin involvement ( 123). In experiments 
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where two rats are parabiosed, allowing exchange of circulating factors, when one has a 
ventromedial hypothalamic lesion it becomes obese and the partner loses fat and lean 
body mass ( 124 ). Many other metabolic abnormalities accompany the obesity induced by 
hypothalamic lesions and appear to be secondary to the observed increase in insulin 
secretion (125). However, animals with ventromedial hypothalamic lesions have lowered 
sympathetic activity and do not appear to be hypertensive, and consequently are also 
inadequate models for the study of Syndrome X. 
The only well known experimentally induced model for Syndrome X, which 
includes obesity, dyslipidemia, hypertension and hyperinsulinemia is high fat feeding. 
Epidemiological data show a strong correlation between body weight and blood pressure 
( 126). There is a great deal of evidence describing this relationship, and although 
insulin is thought to play a role, the cause and effect relationships are not clear (33 - 36, 
38, 42 - 46, 49, 53, 56, 126). In 1939, Wood and Cash, developed an experimental model 
of obesity-induced hypertension produced by high fat feeding in the dog (127). A recent 
resurgence of research in this area, by Rocchini, Hall and colleagues (128, 129) has 
resulted in further characterization of this model. Blood pressure increases in parallel 
with weight gain and is associated with tachycardia and increased cardiac output in dogs 
fed high fat (129). Renal blood flow, GFR and filtered sodium load are increased during 
the development of obesity in this model (129). Thus, a parallel shift toward higher 
blood pressures of the pressure natriuresis curve is observed, with �o change in slope 
(130). Although renal changes have been the main focus of the groups studying this 
model, but insulin sensitivity and the effects of insulin resistance on peripheral vascular 
resistance have been investigated at the systemic level (131). 
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Obesity-induced hypertensive dogs are hyperinsulinemic and exhibit the impaired 
glucose tolerance characteristic of Syndrome X (131). Additional insulin infusion does 
not cause the typical decrease in peripheral vascular resistance obseived in normal dogs 
(131, 132), suggesting that the vasculature of these dogs is resistant to the vasodilatory 
actions of insulin. Furthermore, chronic hyperinsulinemia in these animals does not 
further raise the blood pressure, suggesting that insulin does not increase blood pressure 
by increasing sympathetic output (131). Unfortunately, the manifestations of vascular 
insulin resistance in vitro, such as insulin's effects on intracellular calcium regulation, 
have not been investigated in this valuable model which mimics Syndrome X. 
Unlike dogs, inbreeding of rats for medical research allows interesting 
observations to be made as different strains react to high fat feeding. High fat diets 
have been reported to increase and decrease plasma insulin in rats. Sprague Dawley rats 
fed high fat diets are hypoglycemic, hypoinsulinemic and exhibited lower body weights, 
with increased fat pads weights. In addition, fat feeding decreases adipocyte glucose 
transport and basal (GLUTl) and insulin stimulated (GLUT4) glucose transporter 
concentrations (133). There were major flaws in this study, as the energy percent of 
protein in the diet was significantly different (26% normal versus 15% high fat). Energy 
intake was comparable between both groups, but extremely high fat diets may be 
relatively unpalatable and induce steatorrhea (133). In another study, Sprague Dawley 
rats fed high dietary fat, combined with sucrose, exhibited decreased glucose tolerance 
and insulin sensitivity; however these effects were not attributed to high fat intake, as 
increased sucrose alone had the same effects. Furthermore, increased dietary fiber or 
exercise did not improve insulin resistance (134). In a subsequent study, skeletal muscle 
glucose transporter expression was elevated in high fat fed rats compared to high 
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carbohydrate or normally fed rats. Again, the high fat fed rats were hypoinsulinemic 
with lower blood glucoses than control animals. ( 135) 
In contrast, others have found that hyperglycemia, hyperinsulinemia and weight 
gain accompany high fat feeding in normal rats ( 136 - 139). Blood pressures in Sprague 
Dawley rats fed high polyunsaturated fats and high saturated fat diets were increased 8% 
and 17%, respectively. Rats fed the saturated fat diet had fasting insulin levels 38% 
above control ( 136). Two rat strains, one that becomes obese (S 5B PL) versus one that 
does not (Osborne-Mendel) with high fat feeding, were compared on high fat diets and 
both exhibited decreased sensitivity to insulin; however, there was no significant 
difference between strains (138). In addition, inbred Fischer 344 female rats fed a high 
fat (39.5% ), high sucrose (39.5%) diet for two years were heavier, insulin resistant, 
hyperinsulinemic, hyperlipidemic and hypertensive in comparison with siblings fed low fat 
{6%), complex carbohydrate diets. Viscoelasticity (a measure of clotting activity) was 
higher in the high fat sucrose fed rats. The risk factors clustered in most of the high fat 
sucrose fed animals, although not every animal exhibited increases in every risk factor. 
Moreover, in the low fat, complex carbohydrate group there was no aggregation of and 
few increases in risk factors (139). 
At the molecular level, concentrations and activity of some enzymes involved in 
lipid biosynthesis and lipolysis appear to be directly affected by the amount of fat in the 
diet in rats. In Sprague Dawley rats, increased dietary fat results in liver and adipose 
fatty acid synthase activity suppression (140). The suppression was more exaggerated on 
high saturated than unsaturated fat diets, while adipose FAS was suppressed equally 
(140). 
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It appears that the genetic background of some animals, like people, make them 
more susceptible to deleterious consequences of high fat intake. In addition, the 
methodologies of studying the effects of high fat vary widely. Following is a list of 
questions which must be asked when comparing the literature on high fat feeding. What 
was the percentage of fat used? What was the composition of fats fed? Did the animals 
gain weight? If not, was satiety value or palatability of the diets different? Did the 
animals exhibit steatorrhea? Were micronutrients adjusted for caloric value per gram of 
diet? Was there cholesterol in the fat diet? All of these factors may dramatically 
change the outcomes of high fat diet studies and thus should be carefully considered. 
G. Genetic influences on obesity, insulin resistance and hn,ertension 
Causative links of both genetics and environment to obesity, hypertension, and 
Syndrome X have been demonstrated. From an evolutionary perspective, the thrifty 
genotype hypothesis maintains that the ability to store scarce fuels during periods of 
starvation leads to obesity, associated dyslipidemia and hypertension in "western" 
lifestyles (141). For instance the Pima Indians, Nauruans and Mexican Americans 
exhibit varying combinations of increased risk factors of Syndrome X based on a 
combination genetic and environmental influences (142, 143) 
Syndrome X represents a complicated pathological picture. Individuals exhibiting 
the symptoms of Syndrome X are a heterogenous group; there are undoubtedly several 
genes whose mutations result in this condition. Specific candidate genes studied thus far 
include: apolipoprotein-D (144), lipoprotein lipase (145), low-density-lipoprotein 
receptor (146), insulin (147) and the insulin receptor gene (148). It should also be noted 
that the phenotypes expressed in many people exhibiting Syndrome X are undoubtedly 
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produced by a combination of expression patterns of different genes and thus may be 
described as quantitative traits. 
1. Human pedigree and twin studies 
There are well known associations of genetics and obesity in humans (149). 
When both parents are obese the probability of offspring obesity has been found to be as 
high as 80%. The probability is surely affected by environment as eating habits and 
activity levels are learned from a very early age in most societies ( 149). However, 
adoption studies show the weights of adopted children to be more like their biological 
than adoptive parents. Furthermore, comparison of over 600 pairs of identical and 
fraternal twins reared together or separately showed that even when reared apart, 
identical twins were two times as likely to have similar weights than fraternal twins (150, 
151). 
Most studies of human genetic transmission have used body mass index (BMI) as 
the determinant of obesity. Heritability levels of 20-30% for BMI in nuclear and 
adoptive families are described, while estimates of 60-90% heritability are observed 
between twins (149, 150). BMI transmission assessed across generations in a Canadian 
population with several types of relatives adjusted for age and gender was 35%, however, 
genetics could account for only 5% of transmission (149). Bone structure, percent body 
fat and percent body mass are not considered when using the BMI �s an obesity index. 
A more sensitive analysis of body composition, utilizing under water weighing, performed 
with nine representative relations revealed a 55% transmissible effect, with 25% of the 
variance attributed to genetics (149). 
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Total body fat is a function of energy intake, energy expenditure, the thermic 
effect of food, and nutrient partitioning. There does not appear to be a significant 
genetic effect for habitual energy intake, although a 20% genetic effect on food 
preference for dietary fat and carbohydrate has been reported ( 149). Resting metabolic 
rate (RMR) accounts for approximately 70% of daily energy expenditure; the fat free 
mass is the best predictor for RMR. Residual variance after RMR is adjusted for age 
and gender may reflect heritable differences. The RMRs of monozygotic twins are more 
highly correlated than in dizygotic twins, with 40% of the variance attributable to 
inheritance. In the only study thus far addressing the heritability of the thermic effect of 
food, genetic effects were estimated to be 30% or more (149). Studies of activity level 
contribution to energy expenditure have not revealed significant genetic effects, as 
separating environmental effects has been difficult in humans. Lastly, a single report of · 
genetic transmission of nutrient partitioning characteristics described a genetic 
transmission of 20% ( 149). 
Human pedigree and twin studies of the general population examining all factors 
of Syndrome X have not been conducted. However, there is a heritable syndrome 
referred to as "familial dyslipidaemic hypertension (FDH)" which is similar to Syndrome 
X exhibiting characteristics of hyperlipidemia, insulin resistance, central obesity and 
hypertension . There appear to be several different gene effects resulting in FDH in 
specific subsets, but the metabolic results are similar and significantly influenced by diet 
and physical activity (152). Other extreme cases of insulin resistance result from single 
gene mutations (such as mutations in the insulin receptor) in humans, however people 
suffering from Type A syndrome or leprechaunism, are not likely to reproduce ( 153). 
The study of NIDDM inheritance is a more general analysis of inheritance of insulin 
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resistance. The concordance of dizygotic twins with NIDDM has been shown to be 25%, 
while concordance between monozygotic twins is reported as high as 95% (154). 
Numerous studies have been done to compare the relationships between insulin 
sensitivity and/or blood pressure in different races. The Pima Indians are an especially 
interesting example of a distinct human population which exhibit obesity and insulin 
resistance when employing the westernized lifestyle (141). They have been shown to 
have higher fasting insulin and lower rates of glucose disposal with insulin infusion, 
although mean blood pressure was not significantly correlated with fasting plasma insulin 
in this population (142). 
Lastly the genetic component of familial resemblance of blood pressure has been 
studied across different ethnicities, within and between families, in adoptive families and 
in twins. Whether probands are hypo-, normo- or hypertensive, blood pressures of 
family members are significantly more similar than by chance (155). Obesity also 
aggregates in families and has a marked influence on blood pressure after adolescence 
Studies of different ethnicities are confounded by environmental factors, such as degree 
of ''westernized lifestyle" and socioeconomic status. These factors are accompanied by 
differences in the major factors for determining blood pressure: sodium intake, physical 
activity, obesity and psychological stress. Studies comparing the effects of African 
ancestry versus Caucasian ancestry on blood pressure distribution show significant 
associations between blood pressure and darker skin color (156, 157); however, there 
were no differences seen when these variables were compared in a socially homogenous 
community (158). 
Within and between family studies have consistently shown significant 
correlations of blood pressure in first degree relatives approximately 0.22 for systolic 
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pressure and 0.18 for diastolic pressure, and support the notion that blood pressure is a 
quantitative trait. Siblings generally exhibit higher correlations than parents and 
offspring (155). Adoption studies have also supported a genetic component in the 
transmission of blood pressure, as there is a higher correlation between parents and 
natural childrens than between parents and adopted childrens blood pressures. In 
addition, natural siblings have higher blood pressure correlations than adoptive siblings 
(159). However, the correlations between adoptive or natural children within a 
household are higher than those between parents and natural children; thus, 
environmental factors clearly exert a strong influence (160). The coaggregation of weight 
and blood pressure within families is especially notable (159, 160). 
In a comprehensive historic study of twins, Stocks (161) found correlations of 
0.81 for systolic pressure in monozygotic twins, while same-sex dizygotic twins and same­
sex siblings exhibited systolic pressure correlations of 0.44 and 0.45, respectively. When 
other correlates affecting blood pressure such as height, were accounted for, genetic 
heritability of blood pressure was estimated to be 20-30% (161). 
There are clearly genetic components in obesity, diabetes and hypertension. 
Syndrome X is a newly described clustering of risk factors which encompass, in many 
cases, the above polygenic diseases. Confounding factors in the human population, such 
as household environment, socioeconomic status or psychological stress, make genetic 
contribution and gene-environment interactions very difficult to study. Advances in 
molecular biology, as well as, single or polygenic mutant animal models will allow more 
sensitive analysis of the physiological factors affecting body weight, insulin sensitivity and 
blood pressure. 
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2. Animal genetic models 
Genetic obesity was recognized by Cuenot in 1905 in the yellow mouse ( 162). 
There are now many well known rodent models of genetic obesity; in mice and in rats. 
The obese phenotypes of these models differ in onset, severity, and accompanying 
pathologies such as insulin resistance. Chromosomal locations of seven mutants have 
been established, although only mouse ob and yellow have been cloned. The function of 
the protein products of these genes are currently under investigation. It is suspected that 
the primary defects in these genetic obesities lie in the central nervous system and elicit 
the symptoms of hyperphagia, hyperinsulinemia, autonomic outflow abnormalities and 
altered regulation of the hypothalamohypophysial-adrenal axis (162). 
There are several genetic mouse models which may mimic Syndrome X in 
humans. These mouse mutants are all obese, dyslipidemic and insulin resistant. It is not 
currently known whether these animals exhibit hypertension. The autosomal recessive 
mutants are Diabetes (db), Obese (ob), Tubby (tub) and Fat (fat) loci are located on 
chromosomes 4, 6, 7, and 8 and share homology with regions on human chromosomes 1, 
7, 11, and 16, respectively. The Yellow (Al)') dominant mutant is located on mouse 
chromosome 2, with a human homologue on chromosome 20 ( 163). Recent molecular 
advances coupled with conventional parabiosis experiments are leading to a more 
comprehensive understanding of genetic obesities in the mouse. 
The mouse obese (ob) gene, whose 167 amino acid protein . product (which is 
probably a hormone since it contains a signal sequence) regulates the size of the body's 
fat stores and whose mutation result in gross obesity and NIDDM, was recently cloned 
(164). In some mutants no protein product is formed, while in others a defective protein 
product is overproduced indicating interruption of feedback inhibition. The likely site of 
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action is hypothalamus which controls food intake and energy expenditure (122, 126, 
164). The mouse gene shares 84% homology with the human gene (164). From cross­
circulation experiments the protein product of ob is suspected to be. a circulating factor. 
The ob/ob mice do not have the ability to produce a suspected satiety signal (165). 
These animals exhibit impaired reproductive abilities which may be related to defects 
imparted by the mutant alleles on steroid actions or impaired steroidal actions on allelic 
expression. 
Mice carrying mutations of the db gene, which has not yet been cloned, have 
similar, if not identical obesity-diabetes syndromes as ob/ob mice. These animals fail to 
respond to the same satiety signal that ob/ob mice cannot produce (165). Fascinating 
parabiosis experiments have shed light on the interacting functions of the ob and db 
genes in mice. When an ob/ob mouse is parabiosed to a lean littermate the ob/ob 
mouse loses some weight but does not become lean. When a db/db mouse is parabiosed 
to a lean littermate the littermate stops eating. When an ob/ob mouse is parabiosed to a 
db/db mouse the ob/ob mouse stops eating. Apparently the db/db mouse secretes a 
satiety signal to which it cannot respond but that the ob/ob mouse does not produce but 
can respond to (165). It also suggests that the db protein product is the receptor through 
which ob acts (166). The db/db mouse does not exhibit impaired reproductive capacity 
as observed in the ob/ob mouse (162). 
The viable yellow mouse (AVJ/-) carries a mutation near the. locus of the agouti 
gene which results in obesity, insulin resistance and a yellow coat color. The agouti 
protein gene has been mapped to mouse chromosome 2 and cloned. It codes for a 131 
amino acid protein with a signal sequence (166, 167). Normally, agouti is involved in 
determining coat color as it regulates different pigment production ( eumelanin versus 
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phaeomelanin) in the environment of the mouse hair follicle in a paracrine fashion (166, 
167). The lethal yellow mutation is the result of a 170 kilobase mutation in a gene called 
Raly which has the same transcriptional orientation as agouti and maps proximal to the 
agouti gene. In mutant viable yellow Al'Y mice the agouti protein is ectopically expressed 
in nearly every tissue tested ( 167). Thus the agouti protein is active in general 
metabolism only when mutated in the mouse and produces marked, obesity, insulin 
resistance, impaired responses of adrenergic receptors and tumor production. 
Interestingly, recent studies in our laboratory indicate that ectopic expression of the 
agouti protein may result in altered intracellular calcium metabolism in skeletal muscle, 
which may be a manifestation of insulin resistance (168). 
The human homologue for the agouti protein has recently been cloned and is 
located on human chromosome 20qll .2; it exhibits 80% homology to the mouse agouti 
gene. The human agouti gene produces a 132 amino acid protein with a signal sequence 
and is closely linked to MODY (maturity onset diabetes of the young) which is normally 
active in adipocytes and testis, not muscle or liver ( 167). 
Although it is easier and less costly to study genetic factors in smaller rodents, 
the study of physiological processes is typically easier in larger animals. There are 
several genetic rat models available for the study of genetic obesity, insulin resistance or 
hypertension. The Zucker obese rat is by far the most studied rat model which 
approximates Syndrome X in humans. This double mutant for the fatty (fa) allele 
exhibits many if not all of the symptoms associated with syndrome X; they are 
hyperlipidemic, hyperinsulinemic, hypertensive and obese ( 169 - 173). 
The location of the fatty gene is on rat chromosome 5 ( 174 ). The gene is 
flanked by the interferon alpha (/fa) gene and the facilitative glucose transporter (Glutl), 
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similar to the db gene loci on mouse chromosome 4. lfa and Glutl are linked to fa in the 
gene order lfa-fa-Glutl ; the same occurs in the db mouse (Ifa-db-Glutl), suggesting that 
db and fa are mutant alleles of a homologous gene. (174) Therefore, we may speculate 
that the db and fa may code for the receptor of the protein encoded by ob. 
Attempts to characterize the development of obesity and insulin resistance have 
led to the following pathological time line. Obesity is present in obese Zucker rats at 
age 3 to 5 weeks when compared to lean (Fa/Fa) siblings ( 175). Hyperinsulinemia 
appears as early as 3 to 4 weeks {169), with increased insulin concentration and glucose 
stimulated release (172). Hypertriglyceridemia and glucose intolerance are present by 
age 1 1  to 13 weeks (169, 176). While some investigators have found hyperglycemia in 
obese Zucker rats, others have not ( 177, 178). Nonetheless, skeletal muscle glucose 
transport is lower in obese animals (179 - 181). Obese Zucker rats are also hyperphagic 
to a described "breakpoint", which may be reached with the maximal possible size of each 
individual animal. The magnitude and duration of hyperphagia is influenced by dietary 
components; animals on a high fat diet reach this breakpoint sooner (182). 
The obese Zucker rat has been extensively studied as a model of hypertension. 
Blood pressure studies of obese versus lean Zucker rats are conflicting; however, with 
direct arterial measurements in conscious, unrestrained animals it has been consistently 
demonstrated that obese Zucker rats are hypertensive by as early as six weeks of age 
(83, 87, 100, 170, 183 - 185). Renal damage is present by at least three months of age, 
with proteinuria, glomerular mesangial matrix expansion and increased number of 
glomeruli with hypertrophy. However, GFR is still normal at this age. Hypertension 
and hyperlipidemia precede the overt renal damage and may both contribute to 
glomerulosclerosis and proteinuria (170). 
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Obese Zucker rats exhibit abnormal sympathoadrenal function and abnormal 
plasma catecholamines (170). It has been shown that obesity in the Zucker rat is in part 
reversible upon adrenalectomy. Readministration of glucocorticoids restores the 
metabolic defects which lead to obesity (177). Therefore there may exist steroid 
responsive elements in the sequences controlling the expression of fa which are more or 
less regulated as a result of the fatty mutation. 
Obese Zucker rats have increased number and size of adipocytes. Fatty acid 
synthesis is highest in young fatty rats and gradually declines until there are no 
differences between obese and lean siblings. There is increased activity of adipocyte 
malic enzyme, acetyl-CoA carboxylase, 6 phosphogluconate dehydrogenase and fatty acid 
desaturase when obese animals are not food restricted. The increases in these enzymes 
levels or activities accompany an increased rate of lipogenesis (177) . 
The homozygote-wild type and the heterozygote siblings of obese animals have 
been considered lean, thus the fa allele has been considered recessive ( 174). However, 
several investigators have shown that there are phenotypically intermediate lean animals 
which may be representative of animals carrying one copy of the fa allele (186). 
Establishment of a Brown Norway /Zucker cross allows identification of polymorphic 
genetic markers tightly linked to the fa mutation ( < 0.5 cM from /a) ( 187). Offspring of 
these crosses can be used from a very early age to determine the effects of carrying zero, 
one or two copies of the fa allele ( 186). 
H. Dietazy influences on obesity, insulin resistance and hypertension 
It is well known that environmental activities such as eating and exercise play a 
crucial role in determining body weight, blood pressure, and insulin sensitivity despite an 
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organism's genetic background (129, 130, 134 - 136, 188 - 194). Numerous studies have 
looked at the relationship of carbohydrate or fat feeding and various vitamins and 
minerals on the risk factors of cardiovascular disease. The contents of several nutrients 
are exaggerated in urbanized diets and have received attention in the studies of obesity, 
insulin resistance or hypertension. For instance, calcium is typically reduced (194) while 
sodium and fat are in excess (21, 190, 194). Studying the relationship of these nutrients 
to disease in human beings is difficult due to the colinearity of nutrients, dietary form 
and inadequate assessment techniques ( 190). 
Louis K. Dahl recognized that genetic, as well as environmental factors such as 
weight gain, contributed to variations in observed blood pressure responses to salt intake. 
( 129). He discovered a rat model (Dahl salt sensitive or salt resistant) of salt­
resistance/salt sensitivity and showed in cross-transplantation studies that salt sensitivity 
leading to hypertension followed the kidney. However, the contribution of sodium intake 
to the clustering of other risk factors of cardiovascular disease has been studied by few. 
As previously discussed, in humans and animals acute administration of insulin increases 
renal sodium reabsorption (69, 73). Conversely, there appears to be a relationship of 
sodium intake with insulin sensitivity. Donovan et al. reported significant decrements in 
insulin sensitivity in normal subjects on high sodium diets (191). One suspected 
mechanism underlying the decrease in insulin sensitivity with high sodium intake is a 
sodium-mediated increase in free fatty acids and resultant substrate _competition with 
down regulation of glycolytic enzymes (191). 
The role of dietary calcium in hypertension has also been studied intensively. In 
a recent review, metanalysis of several studies showed reduced dietary calcium intake is 
frequently associated with human and animal hypertension. In general it appears that 
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calcium supplementation results in a prophylactic effect on the development of 
hypertension in animals and humans, but has not yet been shown to have therapeutic 
effects on already established high blood pressure (190). The relationship among dietary 
calcium, calcemia and hypertension seems paradoxical. While dietary supplementation of 
calcium seems to lower blood pressure, both hypocalcemia and hypercalcemia have been 
observed in hypertensive states. Calcitrophic hormones are also altered in hypertensives 
with increases in parathyroid hormone and decreases in calcitriol present. 
Epidemiological data supports a positive relationship among serum calcium and blood 
pressure and negative relationship between calcium intake and blood pressure (19, 190). 
Weight gain has been recognized as a contributor to essential hypertension in 
both animal models and humans (55, 56, 73). The association of increased blood 
pressure with aging is highly correlated with weight gain. Weight loss can reduce blood 
pressure independently of sodium intake (73, 129) Furthermore, weight gain is also 
highly associated with the development of insulin resistance and hyperinsulinemia, 
although insulin resistance occurs in many lean hypertensives as well (55). 
The incidence of cardiovascular disease is highly associated with diets that are 
high in fats, particularly saturated fats (136). As previously discussed, high fat feeding, 
with or without weight gain, has been shown to induce or exaggerate hypertension in 
both normal and obese animal models (129, 136, 139). High levels of dietary fat also 
contribute to the development of obesity, atherosclerosis, ischemic �eart disease and 
various cancers. Reduced fat diets alone and coupled with exercise have been shown to 
dramatically reduce the risk factors of Syndrome X in humans (192). 
Studying the associations of high fat diets with cardiovascular risks in human 
populations can be highly problematic. For instance, vegetarians have frequently been 
51 
compared to omnivores, as they tend to eat less fat, particularly saturated fats. Seventh 
Day Adventists, who are predominantly lacto-ovo-vegetarians, have a very low incidence 
of morbidity and mortality from cardiovascular diseases. However, Seventh Day 
Adventists beliefs cause them to abstain from many other potentially harmful substances 
such as alcohol (195). Rouse et al. got around this problem by comparing Adventist 
vegetarians to Mormon omnivores whose religious habits also eliminated alcohol, 
caffeine and other confounding foods and beverages. Adventists had significantly lower 
blood pressures, total fat intake, saturated fat intake and cholesterol than the Mormons 
(196). In general most studies indicate that decreasing dietary fat in humans results in a 
decrease in blood pressure (197). 
Fewer studies are available which study the relationship of dietary fat with other 
risk factors of Syndrome X. In the San Luis Valley Diabetes Study, subjects which 
exhibited impaired glucose tolerance were asked to report 24-hour recall of their diet at 
baseline and one to three years after. The people who went on to develop NIDDM had 
the highest dietary fat intake, followed by those who remained glucose intolerant. The 
group which reverted to normal glucose tolerance had the lowest fat intake of all. An 
average 40g/ day increase in dietary fat was associated with 3.4 fold risk of developing 
NIDDM (193). In one of the few dietary fat intervention studies in humans, Barnard et 
al. studied NIDDM, insulin-resistant and normal subjects for three weeks on a low-fat 
(10%; polyunsaturated /saturated fat ratio = 1.24) and treadmill ex�rcise regimen. All 
groups exhibited significant decreases in cardiovascular risk factors, and the NIDDM 
group had the greatest changes. Insulin, blood pressure, triglycerides and BMI were 
reduced; thus it is difficult to tell whether these positive effects were due to weight loss, 
decreased dietary fat, increased activity level or a combination of all three (192). 
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In reviewing studies of the effects of high fat diet on cardiovascular risk factors, 
the quality of fat in the diets must be scrutinized (198). In a recent review, Iacono and 
Dougherty reported results from 18 studies with varying increases in the polyunsaturated 
fat linoleic acid. Twelve studies showed significant decreases in blood pressure with 
linoleic acid addition or vegetarian diet in normotensive individuals, while 4 showed 
lowered blood pressures in hypertensive individuals (198). Linoleic acid an omega-6 
(18:2) fatty acid, found in seed oils, is the precursor of arachidonic acid which is the 
precursor for the 2-series prostaglandins. Formation of different prostaglandins is 
enzyme and tissue specific. With increased percentage of linoleic acid of total fat intake, 
increased prostacyclin is produced in the kidney, and salt and water excretion increases 
leading to lowered blood pressures. In addition, prostacyclin acts as a vasodilator, and 
may thereby decrease total peripheral resistance. However, increased arachidonic acid 
also increases thromboxane A2 ( a vasoconstrictor) production. 
Saturated fat intake has been found to be the most important predictor of plasma 
cholesterol. Pronczuk et al. have recently described the variations in gerbil plasma 
cholesterol caused by different dietary fat compositions to be similar to that found in 
cebus monkeys and humans (199). The most important dietary fat determinant of 
increased cholesterolemia is myristic acid intake ( 14:0). Consistent with evidence 
discussed previously, dietary 18:2 decreased cholesterolemia. It was concluded that 
dietary 14:0 and 18:2 are the fatty acids which modulate plasma cholesterol during low 
cholesterol intakes. Therefore diets high in 14:0 may lead to increased cardiovascular 
risk, while diets high in 18:2 may reduce cardiovascular risk ( 199) 
As discussed before, it is difficult to tease apart the genetic and environmental 
factors that contribute to cardiovascular disease, but epidemiological, intervention and 
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controlled animal studies have increased our understanding of both. The physiological 
responses of various animal species to high fat feeding were discussed previously in the 
section of this dissertation addressing experimental models of obesity, insulin resistance 
and hypertension. 
I. Diet and gene interactions in obesity, insulin resistance and hn,ertension 
Genetics and diet have been shown to interact in obesity and hypertension in 
humans (155). Individuals with familial dyslipidemia hypertension, who are genetically 
susceptible to coronary heart disease, experience earlier onset of hypertension and 
dyslipidemia with high fat diets (200). However there are few human studies which 
clearly assess the contributions of genetic and environmental factors (155, 193, 198). 
As already established, the obese Zucker rat is a genetic model of syndrome X 
(169 - 185). While the double mutant is the genetic extreme there still appears to be 
some environmental modulation of the phenotype (201 - 208). Hypertensive Zucker 
obese rats exhibit an increased pressor effect to a relatively high salt diet ( 4g/100g), they 
do not show a decreased pressor effect from a relatively sodium-restricted (0.26g/100g) 
diet (203). In addition, lean Zucker rats seem relatively resistant to high fat diets, while 
obese Zucker rats appear sensitive to high fat feeding (202). However, obese Zucker 
rats fed an energy restricted diet, nonetheless, exhibit an obese body composition (201 ). 
Bray et al. showed that weight gain in both lean and obese Zucker rats was accelerated 
by high fat feeding. In addition, adrenalectomy attenuated dietary fat induced weight 
gain in lean and obese animals. Increased lipoprotein lipase activity observed in lean 
animals was not observed in obese animals fed high fat. Hence, genotype, high fat and 
adrenalectomy were found to interact in the development of obesity in Zucker rats (207). 
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Molecular studies indicate that development of lipogenesis, hepatic fatty acid 
synthesis and enzymatic activities are higher in obese Zucker rats compared to lean Fa/? 
rats on any diet. High fat feeding resulted in higher proportions of large-type adipocytes 
in both phenotypes (206). Penicaud et al. found that expression of fatty acid synthase, 
acetyl-CoA carboxylase and Glut4 were all increased in obese versus lean rats fed high 
fat diets. In contrast, high fat feeding in some studies of obese animals has been shown 
to reduce insulin-responsive glucose transporter protein ( Glut 4) and glucose transport in 
skeletal muscle and adipose tissue (135). While liver fatty acid synthase expression and 
activity appear to be suppressed with high fat feeding in normal rats ( 140), this 
suppression does not occur in genetically obese rats (209). In addition, adipsin, a serine 
protease which may play a role in food intake regulation and is secreted by adipocytes is 
suppressed in ob/ob and db/db mice, Zucker obese rats but not in JCR:LA.cp obese rats 
(another rat model of genetic obesity) and may be normalized with high fat feeding 
(142). The results of these and other studies clearly support a gene-diet interaction in 
the Zucker obese rat. Consequently, further studies employing the use of genotyping 
methods ( 187) may allow a more sensitive analysis of these interactions in animals which 
carry one mutant allele (186). 
In conclusion, there are associations among obesity, insulin resistance and 
hypertension in both humans and animals. Hypertension in insulin resistant states may 
be due to some combination of hyperinsulinemia, increased sympathetic activity, renal 
sodium reabsorption or defective cation transport in vascular tissues. The clustering of 
these risk factors present in Syndrome X are clearly influenced by both genetics and 
environment. While the study of gene-environment interactions in humans is difficult, 
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animal models, such as Zucker rats, afford the unique opportunity to assess the 
contribution of both, in a more controlled environment. 
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PART 3 
EXPERIMENTAL INVESTIGATIONS OF RELATIONSHIPS AMONG OBESITY, 
INSULIN RESISTANCE AND HYPERTENSION 
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I. RECOVERY TO BASELINE INTRACELLULAR CALCIUM IS IMPAIRED IN 
FRESHLY ISOLA TED VASCULAR SMOOTH MUSCLE CELLS FROM 
STREPTOZOTOCIN DIABETIC RATS1 
A. Abstract 
We have recently reported that insulin accelerates the rate of intracellular Ca2+ 
([Ca2+li) recovery (i.e. return to baseline) following agonist stimulation in cultured 
vascular smooth muscle cells (VSMC). Accordingly, we predicted that impaired cellular 
responses to insulin, whether due to insulinopenia or insulin resistance, would result in a 
delay in [Ca2 +]i recovery following agonist stimulation, and that such an impairment may 
contribute to exaggerated vascular resistance and reactivity in diabetic states. 
Consequently, we have evaluated the effects of insulinopenia on the ability of VSMCs to 
recover from angiotensin II (AII)-induced Ca2+ loads. Male Sprague-Dawley rats were 
injected with either vehicle or streptozotocin (STZ; 65 mg/kg I.V.) to induce 
insulinopenia, and sacrificed two weeks later for evaluation. Thoracic aortae were 
immediately removed, cleaned, denuded of endothelium, and enzymatically digested to 
release VSMCs. Freshly dispersed cells were then washed, counted, loaded with 10 µM 
Fura-2-AM, and Ca2+ responses to and rate of recovery from All (200 nM) were 
fluorometrically studied in stirred suspensions (106 cells/mL). VSMCs from the STZ 
(n = 5) and control (n = 8) groups exhibited similar baseline [Ca2+L levels as well as 
1This manuscript has been submitted for publication in similar form with co-author 
Michael B. Zemel. 
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comparable peak responses to All. However, the S1Z VSMCs exhibited a marked delay 
in the rate of [Ca2+L recovery to baseline following All stimulation (2.4± 1 .2 nM/min vs. 
8.4± 1 .2 nM/min in VSMCs from S1Z and control rats, respectively; p < 0.03). These 
data support the concept that inability of insulin to stimulate [Ca2+]i recovery in 
insulinopenia may contribute to exaggerated vasoconstrictor responses in diabetic states. 
B. Introduction 
Individuals with both insulinopenia and insulin resistance exhibit increased risk of 
high blood pressure, although the pathogenesis of hypertension in these diabetic states 
differs ( 1 ). Overt hypertension in Type I diabetes generally develops after the onset of 
renal disease; however, there is evidence suggesting that exaggerated vascular smooth 
muscle reactivity may precede renal dysfunction ( 1). Reports of hypertension in animal 
models of insulinopenia have varied with animal age and with methods of induction of 
insulinopenia and for blood pressure measurement (2-4 ). It appears that directly 
recorded, resting, intra-arterial blood pressure is similar in streptozotocin-induced 
diabetic rats and controls. In contrast, S1Z diabetic animals restrained for tail-cuff 
blood pressure measurement exhibit higher blood pressures than controls (2). Increased 
vascular sensitivity to catecholamines is observed in chemically-induced diabetic rats as 
early as 5 weeks after p cell destruction (5). Impairment of acetylcholine-induced 
relaxation in streptozotocin-treated rats has also been reported ( 5) . .  
The increase in blood pressure in insulin resistance has been attributed to high 
circulating levels of insulin and resultant increases in both sympathetic tone and renal 
sodium retention (1). However, we have recently reported that hypertension in insulin 
resistance states is maintained under ganglionic blockade and is, therefore, independent 
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of sympathetic neural support ( 6). In addition, we and others have recently shown insulin 
to attenuate intracellular calcium and vasoconstrictor responses to pressor agonists in 
both animal models of hypertension and humans (7 - 14). Chronic insulin infusion in 
dogs ( 13, 14) and in normal humans results in decreased peripheral vascular resistance 
and blood pressure (8, 9). Accordingly, we have proposed that a vascular smooth muscle 
manifestation of insulin resistance, rather than hyperinsulinemia, may be responsible for 
the increased peripheral vascular resistance characteristic of insulin resistant states. This 
would suggest that hypertension and exaggerated pressor responses in insulinopenic 
states may result from loss of insulin-induced vasodilation. 
Previous studies in this laboratory have shown that cultured vascular smooth 
muscle cells incubated with insulin exhibit a more rapid recovery from agonist-induced 
. . 
calcium loads than control cells ( 10). Further, freshly isolated vascular smooth muscle 
cells from insulin resistant Zucker obese rats exhibited significantly slower intracellular 
calcium recovery rates than those from the normal Zucker lean rats (15). Accordingly, 
the objective of the present study was to determine whether freshly isolated cells from 
experimentally-induced insulinopenic rats exhibited impairments of vascular smooth 
muscle calcium regulation as compared with control rats. 
C. Materials and Methods 
Male Sprague Dawley rats were fed nonpurified diet (Agwar Prolab Rat Mouse 
Hamster 3000, Syracuse, NY) and given water ad libitum in a controlled environment 
(21°C) with a 12 h light:dark cycle. This study was approved by the University of 
Tennessee Institutional Animal Care and Use Committee. 
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At five weeks of age 16 rats were injected in the tail vein with 65 mg/kg 
streptozotocin (n = 8) or citrate buffer (n = 8) vehicle solutions in 0. 1 - 0.2 ml volume, 
pH = 4.5. Streptozotocin is a nitrosourea which results in degranulation and selectively 
destroys the J} cells of the pancreas. Injection of 40 - 65 mg/kg results in marked 
hypoinsulinemia (1) and hyperglycemia in most animals ( 1  - 5). 
After two weeks and an overnight fast, rats were anesthetized with sodium 
pentobarbital (50 mg/kg), weighed and venous blood glucose was analyzed (Accu­
Cheklll, Boehringer Mannheim Diagnostics, Indianapolis, IN). Vehicle-injected rats (n 
= 8) and streptozotocin-injected rats ( only animals with fasting blood glucose greater 
than 300 mg/ dL, n = 6) were sacrificed by aortic transection. 
Thoracic aortae were cleaned in HEPES buffer (HBSS), pH 7.4, containing 138 
mM NaCl, 1.8 mM CaC12, 0.8 mM MgS04, 0.9 mM NaH2P04, 4.0 mM NaHC03, 25 mM. 
dextrose, 6 mM glutamine, 20 mM HEPES, and 0.5% bovine serum albumin. After 
removing the endothelium with gentle rubbing, the vascular smooth muscle cells were 
released by enzymatic digestion in HBSS with 20 U/mL elastase, and 260 U/mL 
collagenase. After washing, VSMCs were loaded with Fura-2-AM ( acetylrnethoxyester, 
Calbiochem, San Diego, CA) dissolved in DMSO for a final concentration of 10 µM and 
incubated at 37° C with gentle shaking. After 20 minutes for loading and de­
esterification, Fura-2 loaded cells were washed and placed in stirred suspension. 
Intracellular calcium was measured fluorometrically (Hitachi F-2000, Naperville, IL -
Appendix A) with dual excitation (340 nm and 380 nm) and single emission (510 nm). 
Angiotensin II (200 nM) was added after a stable baseline calcium was achieved, 
Digitonin (100 mM) and Tris-EGTA (100 mM) were added approximately 300 and 400 
seconds after angiotensin II addition to obtain maximum and minimum calcium values, 
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respectively. Concentrations were calculated using a K0 for Fura-2 of 224 in the 
equation of Grynkiewicz et al. (Appendix A) ( 16). The rate of recovery from peak to 
baseline was calculated by superimposing tracings on graph paper, drawing a best fit line 
and determining the slope of that line. 
Viable cells, as visualized with trypan blue exclusion and counted on a 
hemocytometer, were studied at a density of 106 cells/mL. One streptozotocin 
determination was not included due to experimenter error ( the stirring mechanism was 
turned off). Differences between insulinopenic and control groups were assessed using 
the unpaired Student's t-test assuming equal variances. 
D. Results 
Means ± standard errors (SEM) are reported in Table 1. Initial and experiment 
day body weights were comparable between the two groups although the mean weight 
change in control was higher than STZ (91 g and 65 g, respectively) animals. Plasma 
glucose was 124±.3 mg/dL in the control rats. In the STZ group, only those animals with 
plasma glucose > 300 mg/ dL were studied. A mean plasma glucose for the diabetic rats 
cannot be reported, as readings above 400 are beyond the fidelity of the glucose meter. 
Figure 1 depicts a representative tracing of [Ca2+li  response to angiotensin II in stirred 
VSMC suspension. 
There were no differences in basal cell calcium or peak responses to AIi 
stimulation between vascular smooth muscle cells from streptozotocin and vehicle­
injected controls. However, there was a marked difference in the rate of recovery from 
calcium loads. Cells from insulinopenic rats were able to clear the transient calcium 
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Table 1. Gross physiological measurements and vascular smooth muscle cellular 
responses to angiotensin II from vehicle- and streptozotocin-injected male Sprague 
Dawley rats. 
VEHICLE STZ 
Initial weight (g) 129 ± 9 142 ± 13 
Experimental weight (g) 221 ± 9 206 ± 9 
Blood glucose1 ( mg/ dL) 124 ± 8 > 300 
Baseline [Ca2+L (nM) 266.2 ± 1 1 .4 260. 1 ± 19.0 
Peak [Ca2+li ( nM) 317.6 ± 10.6 30 1.5 ± 19.3 
Slope of return to baseline 0.14 ± 0.02 0.04 ± 0.02* 
Recovery rate2 (nM/min) 8.4 ± 1 .2 2.4 ± 1.2* 
Data are expressed as mean ± SEM 
1Glucose measurements over 400 are beyond the fidelity of the meter 
2Recovery = rate of return to baseline [Ca2+L levels following agonist stimulation. 
* p < 0.03. 
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increase at less than half the rate observed in cells from vehicle-injected controls 
{p< 0.03, Table 1). 
E. Discussion 
Data from this study demonstrate there is an impairment in the rate of 
intracellular calcium recovery to baseline in isolated VSMC from insulinopenic rats 
compared with VSMC from vehicle-injected rats. These results are consistent with the 
recent report that insulin accelerates the rate of intracellular 
calcium recovery to baseline following agonist stimulation of cultured vascular smooth 
muscle cells (10). Moreover, isolated VSMC from insulin resistant obese Zucker rats 
exhibit similar impairments in calcium metabolism as those from STZ rats (15). The fact 
that this impairment is observed in VSMC from insulin deficient animals suggests that 
reduced VSMC responsiveness to insulin may contribute to increased intracellular Ca2+ 
and consequently, to increased vascular resistance in Type I diabetics. 
It is not clear whether this impairment results from reduction of plasmalemmal 
calcium ATPase expression and/or activity, sarcoplasmic reticulum calcium ATPase 
expression and/ or activity, or some other manifestation of insulin deficiency. Recent 
data from this laboratory has shown that insulin increases the transcription of both 
calcium pumps in cultured vascular smooth muscle ( 1 1  ). In addition, there is reduced 
transcription of both pumps in cells from Zucker obese (insulin resistant) compared to 
Zucker lean (insulin sensitive) rats ( 11  ). Erythrocyte membrane Ca2+ -A TPase pump 
activity has been shown to be decreased both in animal models of diabetes and in Type I 
and Type II diabetic subjects (17 - 20). Moreover, decreased 45Ca2+ efflux has been 
demonstrated in aortae from insulin resistant and insulinopenic rats (21, 22). 
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The relative contributions of baseline or peak [Ca2+L response to agonists versus 
rate of [Ca2+L recovery to the net vasoconstrictor response of a given agonist in vivo is 
not clear. Although force generation by intact blood vessels generally correlates with 
steady state [Ca2+]i levels, vascular smooth muscle is repeatedly subjected in vivo to 
multiple pressor stimuli. Accordingly, the true steady state [Ca2+L condition may be less 
relevant than the ability of the cell to mount a rapid recovery to each agonist-induced 
Ca2+ load. 
We acknowledge that studying VSMCs in stirred suspension may introduce 
artifacts, for example, activation of stretch-dependent channels. Indeed, basal [Ca2+]i in 
the present study was approximately double that observed in cultured cells (10). 
However, we have previously found comparable effects of insulin on VSMCs studies in 
suspension ( 10) vs. coverslips (23). Moreover, study of cells in suspension is unavoidable 
if comparisons of environmental manipulations ( eg. STZ) are to be studied in freshly 
isolated VSMCs, as such non-genetic differences are unlikely to be maintained in culture 
( 15). 
It has been suggested that the increase in glucose transport observed in exercising 
muscle may be, in part, due to the same increased cytoplasmic calcium concentrations 
which allow contraction (24). Further, increased calcium in concentrations too low to 
bring about contraction has been shown to stimulate glucose transport in skeletal muscle 
(24 ). Adequate glycemic control using supplemental insulin has been shown to restore 
normal Ca2+ pump activity and systolic blood pressure in streptozotocin-treated rats, 
suggesting a contributing role of glucose in cellular calcium regulation in diabetic states 
( 4, 7). Therefore, the independent pathways whereby insulin or exercise increase glucose 
transport may result from similar alterations in cytoplasmic calcium. Further, insulin 
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sensitivity and vascular tone would appear to be tightly linked, with an impairment in 
either resulting in increased cytosolic calcium and consequently, a corresponding 
impairment in the other. 
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II. IMPAIRED RECOVERY OF VASCUIAR SMOOTH MUSCLE 
INTRACELLULAR CALCIUM FOLLOWING AGONIST STIMULATION IN 
INSULIN RESISTANT (ZUCKER OBESE) RATS1 
A. Abstract 
We have previously shown insulin to attenuate vasoconstrictor responses to pressor 
agonists and to accelerate VSMC Ca2+ -A TPase mediated ea2+ efflux and vascular 
relaxation. We have now sought to determine if VSMC from insulin resistant Zucker 
Obese (ZO) rats manifest exaggerated [Ca2+L responses to pressor agonists and impaired 
[Ca2+]i recovery (rate of [Ca2+L return to baseline) compared to their lean controls (ZL). 
Thoracic aortae from ZO and ZL were enzymatically digested to release VSMC (n = 16 
animals/group and 8 determinations using 2 aorta each/group). Freshly dispersed cells 
were washed, counted, loaded with Fura-2-AM, and [Ca2+L responses to and rate of 
recovery from angiotensin II (All; 200 nM) and arginine vasopressin (A VP; 10 µM) 
were studied fluorometrically in stirred suspension ( 106 cells/mL). Peak [Ca2+L 
responses to A VP were not significantly different in ZO vs. ZL, while responses to All 
were higher in ZL ([Ca2+L 180± 7 vs. 160±4% of baseline in ZL and ZO, p < 0.02). Since 
we have recently shown insulin to increase All-releasable Ca2+ stores in sarcoplasmic 
reticulum (unpublished data), this increase in peak [Ca2+]i response to All in ZL may 
reflect relative VSMC insulin resistance in ZO. Despite their incre�sed peak All 
1This manuscript has been published in similar form with co-author Michael B. Zemel 
in: American Journal of Hypertension 1993;6:500-504. 
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response, ZL exhibited a more rapid recovery from both the AIi-stimulated load 
(recovery rate = 66.1±8.9 vs. 42.1±9.0 nM/min in ZL and ZO, p < 0.02) and the A VP­
stimulated [Ca2+]i load (22.2±2.3 vs. 18.4±4.6 nM/min). Consequently, we propose that 
the exaggerated vasoconstrictor responses associated with insulin resistance may result, 
in part, from failure of insulin to stimulate VSMC Ca2+ pump activity and thereby 
accelerate recovery from [Ca2+L loads. 
B. Introduction 
The role of hyperinsulinemia versus that of impaired insulin action in the 
pathogenesis of hypertension in insulin resistance is a topic of increasing controversy. 
Hypertension in insulin resistant states has been attributed to selective insulin resistance 
( 1 ), in which skeletal muscle and adipose tissue exhibit resistance, while renal and 
sympathetic nervous system responses to insulin are preserved. Accordingly, the 
hyperinsulinemia resulting from this selective insulin resistance is thought to result in 
increased sympathetic neural output and renal sodium retention and thereby increase 
blood pressure (2). However, a growing body of evidence suggests an alternative; that 
insulin exerts vasodilatory effects and that vascular smooth muscle manifestation of 
insulin resistance results in a partial loss of this insulin-mediated vasodilation. 
Consistent with this latter concept, Hall et al. (3, 4) have reported that chronic 
insulin infusion in normal dogs results in decreased blood pressure and peripheral 
vascular resistance. Similarly, insulin infusion results in vasodilation and decreased 
peripheral vascular resistance in normal humans (5 - 8). Indeed, Anderson, et al. (6, 7) 
reported that insulin infusion during euglycemic clamp studies of both normal and 
hypertensive individuals resulted in decreases in peripheral vascular resistance despite 
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increases in muscle sympathetic nerve activity. Thus, although insulin does appear to 
stimulate increased sympathetic neural output, it does not appear to directly exert 
hypertensive effects, but instead exerts hypotensive action. Further, we have recently 
reported that the hypertension observed in an animal model of insulin resistance, the 
Zucker obese rat, can not be attributed to increased sympathetic neural output, as blood 
pressure differences between Zucker obese rats and lean controls were maintained under 
ganglionic blockade (9). 
Insulin appears to exert several direct effects on vascular smooth muscle which 
may explain its vasodilatory actions. We have found insulin to attenuate in vitro 
vasoconstrictor responses to pressor agonists ( 10), and that this effect is blunted in 
vascular smooth muscle from Zucker obese rats compared to their lean controls ( 1 1  ). 
Moreover, we have found insulin to accelerate the rate of both vascular smooth muscle 
plasmalemmal Ca2+-ATPase-mediated Ca2+ efflux and vascular relaxation (12, 13). 
Recently, we reported that insulin accelerates the rate of intracellular Ca2+ 
([Ca2+L) recovery following stimulation of cultured vascular smooth muscle cells with 
angiotensin II or arginine vasopressin (14). The peak [Ca2+l i responses to angiotensin II 
(but not arginine vasopressin) were increased in insulin-treated cells (14). We attribute 
the latter effect to insulin stimulation of sarcoplasmic reticulum Ca2+-ATPase expression 
( 18), resulting in increased sarcoplasmic reticulum Ca2+ stores to be released following 
angiotensin II stimulation. Nonetheless, the acceleration of Ca2+ recovery time resulted 
in a reduction in the area under the intracellular ea2+ response curve. Accordingly, in 
the present study we sought to determine whether vascular smooth muscle cells isolated 
from insulin resistant (Zucker obese) hypertensive rats manifest an impairment in the 
ability to recover from agonist-induced intracellular Ca2+ loads. 
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C. Materials and Methods 
Zucker lean and obese rats were obtained from Charles River Inc. (Wilmington, 
MA). The fluorescent dye Fura-2-acetylmethoxyester (Fura-2-AM) was purchased from 
Calbiochem (San Diego, CA) and dissolved in DMSO. Collagenase, elastase, angiotensin 
II (All), arginine vasopressin (A VP) and digitonin were obtained from Sigma Chemicals 
(St. Louis, MO). Digitonin was prepared in distilled water and collagenase and elastase 
were mixed in a HEPES-buffered salt solution (HBSS) containing 138 mM NaCl, 1.8 
mM CaC12, 0.8 mM MgS04, 0.9 mM NaH2P04, 4 mM NaHC03, 25 mM D-glucose, 6 
mM glutamine, 20 mM HEPES and 0.5% bovine serum albumin, pH 7.4. AIi and A VP 
were prepared in serum-free HBSS. 
Male Zucker lean (n = 16) and obese (n = 16) rats were anesthetized with sodium 
pentobarbital (50 mg/kg) and thoracic aortas were excised. Two aortas were pooled for 
each replicated determination. Blood and debris were removed by rinsing with cold 
HBSS. The intact aortas were then digested with collagenase (260 U /mL) and elastase 
(20 U/mL) for 15 minutes at 37° C. The vessels were then opened longitudinally, the 
endothelium was removed by gentle rubbing, and the vessels were cut into fine pieces. 
The minced aortas were further digested in the enzymes with occasional disruption by 
shaking to release the smooth muscle cells. Dispersed cells were then filtered, washed 
with HBSS and counted. Viable cells determined by trypan blue exclusion and counted 
with a hemocytometer were used at an approximate density of 106 cells/mL. 
Cell suspensions were immediately chilled on ice for at least ten minutes prior to 
Fura-2-AM addition for [Ca2+L measurement. Fura-2 loaded cells were incubated in the 
dark for 20 minutes at 37° C with shaking, washed with HBSS and resuspended 
immediately prior to [Ca2+L determination. Intracellular calcium was determined using 
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dual excitation (340 and 380 nm) and single emission (510 nm) fluorometry (Hitachi, F-
2000, Naperville, IL) essentially as previously described (15, 16) (Appendix A). 
However, freshly dispersed cells were studied in stirred suspension rather than cultured 
cells being studied in monolayer. 
After a stable baseline was established, agonists (200 nM AIi or 10 µM A VP) 
were added. Three minutes were then allowed for the cells to recover fully from the 
agonist-induced [Ca2+L load prior to addition of digitonin (25 µM) and Tris/EGTA (100 
mM/100 mM, pH 8.7) to determine maximal and minimal calcium fluorescence ratios, 
respectively. The concentration of intracellular calcium was calculated by the computer 
internal to the fluorometer from data points collected every 0.5 seconds using the 
equation of Grynkiewicz et al. (Appendix A) (17). 
Recovery of intracellular calcium loads from AII and A VP-induced stimulation was 
determined from the rate of recovery to baseline after reaching maximal agonist-induced 
[Ca2+]i levels. All data were analyzed for differences between lean and obese rats using 
the unpaired Student's t-test assuming equal variances. 
D. Results 
Typical tracings illustrating characteristic [Ca2+L responses to All in cells from 
lean and obese rats are shown in Figure 2, and the data are summarized in Table 2. 
Peak [Ca2+L responses to All were greater in the lean than the obese rats (p < 0.02). 
However, the rates of recovery from All-induced [Ca2+L loads were decreased by 
approximately 36% in cells from obese compared with cells from lean animals. Despite 
the reduced peak [Ca2+] i response to All in cells from the obese animals, the 
prolonged recovery rate resulted in an increase in the area under the [Ca2+L response 
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Characteristic tracings of the intracellular Ca2+ response to angiotensin II . 
in vascular smooth muscle cells isolated from Zucker lean (upper panel) 
and obese (lower panel) rats. Angiotensin II was added at approximately 
+ 100 seconds followed by digitonin and Tris-EGTA at + 400 and + 500 
seconds, respectively. 
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Table 2. Aortic smooth muscle cell responses to angiotensin II (All) and arginine 
vasopressin (A VP) in Zucker lean and obese rats. 
Baseline [Ca2+]i ( nM) 
Response to All ( % )2 
Response to A VP ( % )2 
Recovery from All ( nM/min )3 
Recovery from AVP (nM/min)3 
Area under All Response curve ( nM •sec) 
Area under the A VP Response curve ( nM • sec) 
1Data are expressed as mean ± S.D. 
2Response ( % ) = Peak/Baseline x 100 
Lean1 Obese1 
230 ± 15 237 ± 15 
180 ± 7 160 ± 4* 
151 ± 5  144 ± 5  
66.1 ± 8.9 42.1 ±. 9.2* 
2 1.6 ± 2.3 18.4 ± 4.6* 
17, 1 16 ± 392 23,450 ± 228* 
28,890 ±. 649 42,694 ± 872* 
3Recovery = rate of return to baseline [Ca2+L levels following agonist stimulation. 
*p < 0.02 
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curve. A similar decrease in the rate of [Ca2+]i recovery and an increase in the area 
under the [Ca2+]i response curve in the obese animals was observed when the cells were 
stimulated with A VP. Baseline [Ca2+]i was not significantly different between the two 
groups (Table 2). 
E. Discussion 
Data from this study indicate that vascular smooth muscle cells from insulin 
resistant Zucker obese rats exhibit a decreased rate of return to baseline (i.e. recovery) 
from agonist-induced [Ca2+L loads. This phenomenon appears to be a vascular smooth 
muscle cell manifestation of insulin resistance, as we have recently reported that insulin 
accelerates the rate of [Ca2•1i recovery in cultured rat vascular smooth muscle cells 
following stimulation with either All or A VP (14). Interestingly, insulin also increased 
peak [Ca2+L responses to AU in the cultured cells (14), consistent with our present 
observation that this peak response was greater in vascular smooth muscle cells isolated 
from insulin sensitive (Zucker lean) rats than those isolated from insulin resistant 
(Zucker obese) rats. 
Baseline [Ca2+L levels in the present study were somewhat higher than those 
reported by other investigators (14, 15). It is possible that the difference may result 
from studying cells which may have been traumatized by the enzymatic dispersion 
process used. However, this is unavoidable if freshly obtained vascular smooth muscle 
cells are to be studied in suspension. As an alternative, cells from lean and obese rats 
may be studied fluorometrically as monolayers following serial passage in culture. 
However, it is not clear whether true differences found in vivo would persist during 
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passage in cell culture, and it may be considered more likely that such differences would 
be evident in freshly obtained cells. 
The relative contributions of peak [Ca2+]i response to agonists versus rate of 
[Ca2+L recovery to the net vasoconstrictor response of a given agonist in vivo is not clear. 
Although force generation by intact blood vessels generally correlates with steady state 
[Ca2+L levels, vascular smooth muscle is repeatedly subjected in vivo to multiple pressor 
stimuli. Accordingly, the true steady state [Ca2+]i condition may be less relevant than the 
ability of the cell to mount a rapid recovery to each agonist-induced Ca2+ load. In 
cultured cells, the integrated [Ca2+L response to AIi (i.e. area under the [Ca2+L response 
curve) was decreased in insulin-treated cells despite the increase in peak response (14). 
Similarly, in the present study cells from the more insulin sensitive (lean) rats exhibited a 
reduced area under the AIi [Ca2+L response curve compared to these from the obese 
rats. Cells from Zucker obese rats exhibited both a lower peak and slower [Ca2+]i 
recovery rate, and these animals also exhibit hypertension and exaggerated in vivo and in 
vitro pressor responsiveness. Thus, it may be considered likely that the slower recovery 
rate and corresponding increase in net [Ca2+L exposure ( area under the curve) is of 
greater importance than peak [Ca2+L responses in determining vascular tone in those 
animals. 
Insulin has also been shown to decrease peak [Ca2+]i responses to A VP (14, 15) in 
cultured rat aortic smooth muscle cells by reducing Ca2+ influx through receptor­
operated channels (15) and decreasing voltage-mediated Ca2+ influx (15). However, we 
found no difference in the peak [Ca2+]i response to A VP in cells from the insulin 
resistant obese rats versus those from the lean rats. Thus, insulin regulation of A VP 
receptor-operated vascular smooth muscle Ca2+ channels appears to be preserved in this 
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model of insulin resistance. In contrast, the rate of [Ca2+L recovery following stimulation 
with A VP was blunted in cells from the obese rats suggesting that insulin stimulation of 
[Ca2+L recovery is compromised in smooth muscle cells from insulin-resistant rats. 
We have recently reported that insulin incubation stimulates the expression of 
plasmalemma ea2+ -A TPase in cultured rat vascular smooth muscle cells ( 18) and, 
consequently, accelerates Ca2+ -ATPase-mediated Ca2+ efflux ( 12) and vascular relaxation 
(13). Thus, it is likely that insulin-induced stimulation of [Ca2+L recovery and 
corresponding decreases in the area under the [Ca2+L response curves are mediated by 
the plasmalemmal Ca2+ -A TPase. Accordingly, the decrease in [Ca2+L recovery rate in 
the obese rat in the present study probably reflects an impairment in insulin stimulation 
of Ca2+ -A TPase expression and activity. Indeed, we have previously found reduced 
aortic 45Ca2+ efflux in Zucker obese rats (19) and a comparable decrease in erythrocyte 
ea2+ -A TPase activity in both Zucker obese rats (20) and type II diabetics (21 ). 
We have also recently found insulin to stimulate the expression of sarcoplasmic 
reticulum Ca2+ -A TPase in cultured rat vascular smooth muscle cells (18). If the 
increased expression results in increased sarcoplasmic reticulum Ca2+ -A TPase activity, an 
increase in sarcoplasmic reticulum Ca2+ storage would be expected. This may explain 
the increase in peak [Ca2+L responses to AIi in insulin treated cells (14), as well as the 
diminished [Ca2+]i response to AIi observed in cells from the obese animals. 
In summary, data from the present study provide a cellular rationale for recent 
observations of insulin-induced vasodilation in humans ( 6, 7) as well as insulin-mediated 
acceleration of vascular relaxation (13) and attenuation of in vitro vasoconstriction (10, 
11). We propose that the impaired rate of [Ca2+L recovery in Zucker obese rats results 
from a vascular smooth muscle cell manifestation of insulin resistance. The resistance 
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appears to result in an impairment in the ability of insulin to stimulate both 
plasmalemma and sarcoplasmic reticulum Ca2+ -A TPase. The blunted peak [Ca2 +]i 
response to AIi in Zucker obese rat vascular smooth muscle cells may also result from 
insulin resistance and a consequent failure of insulin to stimulate sarcoplasmic reticulum 
Ca2+ -A TPase, thereby resulting in a diminished AIi-releasable Ca2+ store. Finally, we 
propose that the exaggerated vasoconstrictor responses characteristic of insulin resistance 
may result, in part, from failure of insulin to stimulate one or both Ca2+  -A TPases and 
thereby accelerate recovery from [Ca2+L loads. 
96 
LITERATURE CITED 
1. Reaven GM: Role of insulin resistance in human disease. Diabetes 1988; 
37:1595-1607. 
2. Rocchini AP: Insulin resistance and blood pressure regulation in obese and non­
obese subjects. Hypertension 1991; 17:837-842. 
3. Hall JE, Coleman TN, Mizelle HL: Does chronic hyperinsulinemia cause 
hypertension. Am J Hypertens 1989; 2:171-173. 
4. Brands MW, Mizelle HL, Gaillard CA, Hilldebrandt DA, Hall JE: The 
hemodynamic response to chronic hyperinsulinemia in conscious dogs. Am J 
Hypertens 1991; 4:164-168. 
5. Creager MA, Liang CS, Coffman JD: Beta adrenergic-mediated vasodilator 
response to insulin in the human forearm. J Pharm Exp Tuer 1985; 235:709-714. 
6. Anderson EA, Hoffman RP, Balon TW, Sinkey CA, Mark AL: Hyperinsulinemia 
produces both sympathetic neural activation and vasodilation in normal humans. J 
Clin Invest 1991; 87:2246-2252. 
7. Anderson EA, Balor TW, Hoffman RP, Sinkey CA, Mark AL: Insulin increases 
sympathetic activity but not blood pressure in borderline hypertensive humans. 
Hypertension 1992; 19:621-627. 
8. Neahring JM, Meier T, Hoffmxn RG, Egan BM: Insulin does not antagonize 
forearm vascular alpha-adrenergic reactivity in man. Am J Hypertens 1992; 5:17A. 
9. Zemel MB, Peuler JD, Sower JR, Simpson L: Hypertension in insulin-resistant 
Zucker obese rats is independent of sympathetic neural support. Am J Physiol 
1992; 262:E368-E371. 
10. Zemel MB, Reddy S, Shehin S, Lockette W, Sowers JR: Vascular reactivity in 
Zucker obese rats: Role of insulin resistance. J Vase Med Biol 1990; 2:81-85. 
11. Zemel MB, Reddy S, Sowers JR: Insulin attenuation of vasoconstrictor responses 
to phenylephrine in Zucker lean and obese rats. Am J Hypertens 1991; 4:537-
539. 
12. Ambrozy SA, Sowers JR, Zemel MB: Insulin stimulation of vascular smooth 
muscle Ca2+ pump activity. FASEB J 1991; 5:Al l06. 
13. Zemel MB, Johnson BAB, Ambrozy SA: Insulin-mediated vascular relaxation: 
Role of Ca2+ -ATPase. Am J Hypertens 1992; 5:637-641. 
97 
14. Kim YC, Zemel MB: Insulin potentiates vascular smooth muscle cell (VSMC) 
intracellular Ca2+ ([Ca2+]i) responses to angiotensin II (All) but accelerates 
recovery from [Ca2+L loads. Hypertension 1993;22:74-77 
15. Standley PR, Zhange F, Ram JL, Zemel MB, Sowers JR: Insulin attenuates 
vasopressin-induced calcium transients and voltage-dependent calcium current in 
rat vascular smooth muscle cells. J Clio Invest 1991; 88: 1230-1236. 
16. Standley PR, Gangasani R, Zemel MB, Sowers JR: Human platelet calcium 
measurements. Methodological considerations and comparisons with calcium 
mobilization in vascular smooth muscle cells. Am J Hypertens 1991; 4:546-549. 
17. Grynkiewicz G, Poenie M, Tsien RY: A new generation of Ca2• indicators with 
greatly improved fluorescent properties. J Biol Chem 1992; 260:3440-3450. 
18. Zemel MB, Iannucci A, Moore JW: Role of insulin in regulating vascular smooth 
muscle Ca2+ -A TPase expression. J Vase Med Biol 1993;4:79-84 
19. Shehin SE, Sowers JR, Zemel MB: Impaired vascular smooth muscle Ca2+ efflux 
and hypertension in Zucker obese rats. J Vase Med Biol 1989; 1278-282. 
20. Zemel MB, Sowers JR, Shehin S, Walsh MF, Levy J: Impaired calcium 
metabolism associated with hypertension in Zucker obese rats. Metabolism 1990; 
39:704-708. 
21. Sowers JR, Standley PR, Ram JL, Zemel MB, Resnick LM: Insulin resistance, 
carbohydrate metabolism, and hypertension. Am J Hypertens 1991; 4:466S-472S. 
98 
Ill. VARIATION OF BLOOD PRESSURES IN LEAN ZUCKER RATS FED LOW 
OR HIGH FAT DIETS.1 
A. Abstract 
The purpose of this study was to determine whether lean (Fa/?) Zucker rats which 
exhibit greater metabolic efficiency in response to a high fat ( 48%) diet also exhibit 
hypertension. Twenty-nine lean (Fa/?) and eleven obese (fa/fa) rats were fed low (12% 
energy) or high (48% energy) fat diets. Food intake and weight change were recorded 
weekly to obtain an index of energy efficiency. After six weeks, direct intra-arterial 
blood pressure was measured in conscious, unrestrained animals. Arterial blood was 
collected for analyses of plasma insulin and glucose. There was no effect of high fat diet 
on blood pressure in obese rats, although obese animals on either diet had significantly 
higher blood pressure than lean siblings (p < 0.05). A positive correlation between blood 
pressure and energy efficiency ratio was present only in lean rats fed the high fat diet 
(r = 0.69, p < 0.01). This relationship was not present when all rats or lean rats on a low 
fat diet. Moreover, lean rats fed the high fat diet with blood pressures above the group 
median also exhibited significantly higher insulin (p<0.02), glucose (p<0.01) and energy 
efficiency ratios (p< 0.01) than those with lower blood pressures. Thus, it appears there 
were two groups of lean animals present, one of which was phenotypically more sensitive 
to high fat feeding than the other. This suggests the possibility of a_ gene dosage effect 
of the fa allele in the Zucker rat. 
1This manuscript has been submitted for publication in similar form with coauthors 
William J. Banz and Michael B. Zemel. 
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B. Introduction 
Obesity, glucose intolerance, hypertriglyceridemia and hypertension are a 
clustering of metabolic and physical aberrations called "Syndrome X" which is closely 
associated with cardiovascular disease ( 1 ). Hyperinsulinemia has been implicated as the 
condition that links this "deadly quartet", although a cause-and-effect relationship has yet 
to be established ( 1 ). Dietary, exercise and pharmacological interventions have been 
intensely studied in an attempt to modify environmental factors contributing to this 
syndrome (2, 3). However, genetics may play a pivotal role in determining 
cardiovascular risk and the response to environmental interventions. 
The obese Zucker rat (fa/fa) has been shown to be a single gene defect animal 
model of insulin resistance. Frank obesity is present in obese Zucker rats by age 3 to 5 
wk when compared to lean (Fa/Fa) siblings ( 4 ). Hyperinsulinemia, hypertriglyceridemia 
and glucose intolerance are present by age 11 to 13 wk (5). While some investigators 
have found hyperglycemia in obese Zucker rats, others have not (5, 6). Nonetheless, 
skeletal muscle glucose transport is lower in obese animals (7 - 9). Obese Zucker rats 
are also hyperphagic to a described "breakpoint" which may be reached with the maximal 
possible size of each individual animal. The magnitude and duration of hyperphagia is 
influenced by dietary components; animals on a high fat diet reach this breakpoint 
sooner (10). 
The obese Zucker rat has been extensively studied as a mod�l of hypertension. 
Blood pressure studies of obese versus lean Zucker rats are conflicting; however, with 
direct arterial measurements in conscious, unrestrained animals it has been consistently 
demonstrated that obese Zucker rats are hypertensive by six weeks of age (11  - 16). In 
addition, vascular tissue from obese animals exhibits increased in vitro vascular 
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reactivity (17) and exaggerated intracellular calcium responses to vasoactive agonists 
(18). 
Genetics and environment have been shown to interact in obesity and hypertension 
in humans. Subjects who are genetically susceptible to coronary heart disease experience 
earlier onset of hypertension and dyslipidemia with high fat diets ( 19). High fat feeding 
has also been shown to induce or exaggerate hypertension in both normal and obese 
animal models (20 - 22). Obese Zucker rats fed an energy restricted diet, nonetheless, 
exhibit an obese body composition (23). While lean Zucker rats seem relatively resistant 
to high fat diets, obese Zucker rats appear sensitive to high fat feeding (24 ). The 
purpose of the present study was to determine whether lean animals which exhibit 
greater metabolic efficiency and reduced insulin sensitivity in response to high fat diet 
also exhibit hypertension. 
C. Materials and Methods 
Animals. Lean Zucker rats (Fa/?) were obtained from Harlan Sprague Dawley 
(Indianapolis, IN) and bred to produce lean (Fa/?) and obese (fa/fa) rats. Females 
were housed in plastic cages with wood shavings through mating and pregnancy until the 
pups were weaned at 21 days. Pups were sexed and the males were placed individually 
in wire hanging cages. All animals were fed nonpurified diet (Agway Prolab Rat Mouse 
Hamster 3000, Syracuse, NY) unless otherwise stated and lived in a_ controlled 
environment (21 °C) with a 12 h light:dark cycle. This study was approved by the 
University of Tennessee Institutional Animal Care and Use Committee. 
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Diet. At age 10 wk, 29 lean (Fa/?) and 11 obese (fa/fa) male Zucker rats were 
randomly assigned to a low (12% energy) or high (48% energy) fat diet (Table 3). The 
12% fat diet was based on the AIN-76™ purified diet for rats and mice. Corn oil 
replaced corn starch in the high fat diet, and protein and essential micronutrient content 
were adjusted to be equivalent on an energy basis. Animals were allowed free access to 
their assigned diet and water. Weekly food intake and body-weight-were recorded- for -the 
duration of the six week study. Energy efficiency was calculated as weight gain (g) 
divided by energy intake (kcal) over the 6 wk feeding period. 
Outcome measures. After 42 - 52 days of diet treatment animals were anesthetized with 
sodium pentobarbital ( 50 mg/kg) and a femoral arterial catheter (PE-10) was implanted, 
exteriorized at the nape of the neck and stored in a tissue culture cap. Forty eight hours 
post-surgery blood pressure was measured directly with a low volume transducer and 
Digimed blood pressure analyzer (Micromed Inc. Lexington, KY) in the conscious 
unrestrained state. The animals were then anesthetized and exsanguinated by cardiac 
puncture. Plasma glucose and insulin concentrations were determined using the standard 
glucose oxidase {Sigma, St. Louis, MO) and radioimmunoassay (INCSTAR, Stillwater, 
MN) methods, respectively (Appendix B). 
Statistics. Two-way analysis of variance (ANOVA) of strain (lean v_s. obese Zucker rats) 
and diet (high vs. low fat), multiple and simple regressions were performed to test for all 
possible relationships of the independent variables. A p value of less than 0.05 was 
considered statistically significant. When two-way ANOV A interactions were significant, 
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Table 3. Components of low (12% energy) and high (48% energy) fat diets 
Component 12% fat diet1 48% fat diet1 
Cornstarch2 55.0 (g/lOOg) 24.T (g/lOOg) 
Corn oil2 5.0 25.5 
Casein 20.0 24.8 
Cellulose 5.0 6.2 
Sucrose 10.0 12.4 
AIN Mineral mix 3.5 4.3 
AIN Vitamin mix 1.0 1.2 
D-1-methionine 0.3 0.5 
Choline bitartrate 0.2 0.3 
Energy 3.86 (kcal/g) 4.80 (kcal/g) 
1 12% and 48% of energy derived from fat 
2Com oil was substituted for cornstarch in the high fat diet. 
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the Least Significant Difference test (LSD) was utilized to distinguish differences in 
group means. 
Based on our initial statistical analysis, we examined two populations of lean 
animals fed high fat diets: those below and those above the median mean arterial blood 
pressure. We then performed Student's t-tests comparing the two groups to see if there 
were statistica.1ly significant differences in insulin, glucose and energy efficiency ratio. 
D. Results 
As expected, obese Zucker rats had significantly higher mean arterial blood 
pressures than lean siblings, regardless of diet (138±2 versus 149±5 mmHg, p < 0.02). 
Simple regression relationships of all lean animals revealed a significant correlation 
between mean arterial blood pressure and blood glucose (r = 0.48, p < 0.05), while 
multiple regression demonstrated significant relationships of mean arterial blood 
pressure with plasma glucose (p = 0.006) and energy efficiency ratio (p = 0.04 ). In the 
lean animals fed the high fat diet, mean arterial blood pressure was significantly 
correlated with weight change (r = 0.62, p < 0.01), blood glucose (r = 0.60, p < 0.02) 
and energy efficiency ratio (r = 0.69, p < 0.01) and insulin had a significant correlation 
with energy efficiency ratio (r = 0.62, p < 0.01) in lean animals on a high fat diet. 
Moreover, multiple regression analysis within this group demonstrated that variation in 
energy efficiency ratio, weight change and insulin accounted for 89% of the variation in 
mean arterial pressure (p < 0.000001 ). As obese animals were included for reference 
purposes only, these correlations can not be evaluated due to the small number of 
animals. Among lean animals on the low fat diet these relationships were not evident. 
The mean values for independent variables are presented in Table 4. 
104 
Table 4. Physiological measurements of lean and obese Zucker rats fed low (12% 
energy) or high (48% energy) fat diets. 
Lean 12% Lean 48% 
Sample size 14 15 
Initial weight (g) 339.7 ± 7.5 348.2 ± 8. 1 
Weight change (g) 95.5 ± 1.9 134.9 ± 6.5b 
Insulin (ng/mL) 23.4 ± 2.7 23.5 ± 4.2 
Glucose (mg/dL) 201.8 ± 12.0 200.9 ± 13.4 
G/1 ratio1 12.2 ± 3.0 12.7 ± 2.5 
MAF2 (mmHg) 140.4 ± 2.8 134.9 ± 3.9 
CEI3 (kcal) 3337 ± 95 3492 ± 81  
EER4 0.029 ± 0.002 0.038 ± 0.002b 
8significant phenotype effect p < 0.05. 
bsignificant diet effect p < 0.05. 
Obese 12% Obese 48% 
5 6 
463.0 ± 10.28 457.5 ± 16.88 
127.0 ± 15.6 184.5 ± 8.4b 
93.9 ± 9.78 104.5 ± 9_3a,b 
329. 1 ± 44.2 3 13.0 ± 25.4 
3.7 ± 0.78 3.2 ± 0.48 
149.3 ± 9.08 148.6 ± 6.68 
3974 ± 106 4018 ± 70 
0.032 ± 0.002 0.046 ± 0.002b 
1G/I ratio is the ratio of plasma glucose (mg/dL) to plasma insulin (ng/mL). 
2The sample sizes for MAP measurements were 12, 12, 4 and 3, as ordered above. 
3CEI = Cumulative energy intake over six weeks. 
4EER = Energy efficiency ratio (weight gain (g)/CEI (kcal)) 
105 
The distribution of blood pressures in lean animals fed the high fat diet 
suggested the presence of two populations of animals (Figures 3 and 4). Accordingly, we 
separated these animals into two groups based on median mean arterial blood pressure 
( 132 mmHg). Those animals with mean arterial blood pressures above the median also 
exhibited increases in energy efficiency ratio (p < 0.01) and plasma levels of insulin (p < 
0.02) and glucose (p < 0.01) compared to those with lower blood pressures (Table 5). 
E. Discussion 
In the present study, feeding lean animals a high fat diet unmasked heterogeneity 
in mean arterial blood pressure, plasma insulin and glucose, and energy efficiency. 
Interestingly, lean animals fed a high fat diet with the highest mean arterial blood 
pressures also had higher circulating insulin and glucose as well as a higher energy 
efficiency ratio. The ability of a high fat diet to raise mean arterial blood pressure was 
related to the ability of a high fat diet to exert a diabetogenic effect and possibly 
promote fat storage. Thus, there appeared to be two populations of lean animals, 
suggestive of a possible fa gene dosage effect that may be environmentally alterable in 
heterozygous animals. 
The obese Zucker rat (fa/fa) is a genetic extreme of obesity and insulin 
resistance. The phenotype is relatively resistant to environmental manipulations which 
would otherwise reduce these pathologies when compared to lean (Fa/?) animals (23). 
In addition, obese animals are relatively sensitive to environmental manipulations which 
would exacerbate obesity and insulin resistance (24 ). Therefore, studies of 
environmental effects on modulation of phenotypical fa gene expression have proved 
difficult in obese animals as they are already at the phenotypical extreme. 
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Figure 3. 
MAP (mmHg) 
Regressions of mean arterial pressure (MAP) and energy efficiency 
ratio (EER) in all lean (Fa/?) Zucker rats, fed a low (12% - squares) 
or high (48% - diamonds) fat diet. The mixed regression line was 
not significant. 
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Regression of mean arterial pressure (MAP) and energy efficiency 
ratio (EER) in Jean (Fa/?) Zucker rats fed a high ( 48%) fat diet (r 
= 0.69, p < 0.01) .  Animals with mean arterial blood pressures below 
and above the median 132 mmHg are shown in squares and 
diamonds, respectively. 
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Table 5. Physiological measurements of lean Zucker rats fed high fat diets grouped 
around the median mean arterial pressure of 132 mmHg. 
Below median MAP Above median MAP 
Sample size 5 7 
Initial weight (g) 354.8 ± 12.7 344.4 ± 15.5 
Weight change (g) 120.2 ± 5. 1 147. 1 ± 10.38 
Insulin ( ng/ mL) 14.8 ± 4.3 32.7 ± 5.98 
Glucose (mg/dL) 165.7 ± 10. 1 212.8 ± 12.88 
G/1 ratio 13.3 ± 1.9 7.7 ± 1.48 
CEI (kcal) 3433 ± 127 3564 ± 121 
EER 0.035 ± 0.001 0.041 ± 0.0028 
MAP (mmHg) 122 ± 3 144 ± 4a 
8significant difference between groups, p < 0.02. 
CEI = Cumulative energy intake, EER = energy efficiency ratio, and MAP = mean 
arterial blood pressure, G/I ratio = glucose (mg/dL) to insulin (ng/mL) ratio. 
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As expected, obese animals in the present study exhibited higher energy efficiency, blood 
pressure, plasma glucose and insulin and greater weight gain than lean siblings that were 
not significantly affected by high fat feeding. 
The effect of a high fat diet on the development of hypertension is related, in 
part, to insulin resistance (20 - 22, 25). Weight gain resulting from increased energy 
efficiency on a high fat diet, despite similar caloric intake, may also result in 
hypertension (21, 26). In addition, insulin resistance, enhanced by dietary fat, may lead 
directly to increased blood pressure at the vascular smooth muscle level, as vascular 
reactivity and cell calcium metabolism is aberrant in this tissue from insulin resistant 
animals (14, 18). Moreover, compensatory hyperinsulinemia, secondary to insulin 
resistance, may result in increased sympathetic activity and renal sodium retention and 
further contribute to hypertension (3 ). 
Until recently it has been impossible to distinguish between genotypes of lean vs. 
obese Zucker rats until later in development, when phenotypic markers ( rectal 
temperature, body weight and fat pad size) are discernible. In addition, distinguishing 
between lean animals who carry zero or one copy of the affected gene has depended on 
the known breeding history of parent animals. Therefore, little research has been done 
to show gene dosage effects of the altered allele (fa), but a few studies have shown lean 
heterozygote (Fa/fa) animals to be phenotypically intermediate on several physical and 
metabolic parameters (27 - 31 ). At 17 days, inguinal fat pad weight and inguinal fat pad 
weight / body weight ratio, as well as inguinal fat pad cell size and number, of lean 
Zucker heterozygotes (Fa/fa) were intermediate between obese (fa/fa) and homozygote 
lean (Fa/Fa) Zucker pups (30). Lipid metabolic enzymes such as lipoprotein lipase and 
6-phosphogluconate dehydrogenase were also intermediately produced in adipose and 
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liver tissue. Insulin binding in brain and liver is reduced in both lean heterozygote 
(Fa/fa) and obese (fa/fa) animals when ·compared to lean homozygote (Fa/Fa) animals 
(27, 29). Dynamic pancreas release of insulin is increased in lean heterozygote (Fa/fa) 
and obese (fa/fa) rats compared to homozygote lean (Fa/Fa) Zucker rats (Blonz et al. 
1985). Also intermediate values in brown adipose tissue thermogenesis have been shown 
in lean Zucker heterozygotes (31 ). 
With the recent discovery of a restriction fragment length polymorphism 
recognized by a human genomic subclone sequence (vc85) in a Brown Norway 
(BN)/Zucker cross, it is now possible to distinguish obese (fa/fa) animals at an early age 
and to identify lean homozygotes (BN/BN) and heterozygote (BN/fa) offspring (32). 
Utilizing this methodology, Truett et. al has shown that there are significant differences 
in body and inguinal fat pads weights at 7 and 14 days of age in the three genotypes for · 
fa in Brown Norway /Zucker offspring (33). It has also been demonstrated that the 
heterozygote effect on body weight increases in magnitude by the fourth week of life 
around the same time the double mutant exhibits a marked increase in body weight (34 ). 
Therefore it seems there is a developmental progression in the expression of the fa allele 
with animals carrying one copy exhibiting phenotypical intermediacy early in life which 
becomes less obvious as animals carrying two copies of fa become the phenotypical 
extreme (33, 34). Moreover, we have recently confirmed heterozygote effects of fa at a 
later age and exacerbation of fa effects with high dietary fat using this model (35). 
The experiments presented here may be useful in validating Brown 
Norway/Zucker offspring carrying/a as sufficient models of obesity, insulin resistance 
and hypertension with appropriate controls (BN/BN). The effects of a different 
background of genes, contributed by Brown Norway, on the traditional Zucker phenotype 
1 1 1  
can now be compared. These data are only suggestive of gene dosage as it is not yet 
possible to genotype Zucker rats without first crossing them with a genetically dissimilar 
strain. Consequently, studies to confirm that fa gene dosage alters the severity and 
developmental progress of obesity, insulin resistance and hypertension in Brown 
Notway /Zucker offspring carrying the fa gene are presently in progress. 
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IV. DIETARY AND GENDER-RELATED EFFECTS OF HETEROZYGOSITY OF 
THE RAT FATTY (fa) ALLELE. 
A. Abstract 
Zucker rats carrying one copy of the obesity gene fa may exhibit intermediate 
phenotypes between lean (Fa/Fa) and homozygous mutants (fa/fa). Offspring of later 
generations of a BN/Crl X Crl:Zucifa Fl intercross that segregates for an RFLP tightly 
associated with the fa gene were genotyped and placed on a 12% or 48% energy as fat 
diet for seven weeks. Approximately 72 hours after femoral arterial catheter 
implantation, blood pressures were measured in the conscious, unrestrained state. 
Heterozygous males on high fat diet had higher mean arterial pressures than 
homozygous littermates (p < 0.03). Although there were no differences in energy 
utilization between genotypes, females were less efficient than males (p < 0.0001 ). 
Moreover, males fed high fat diet were more efficient than those consuming low fat diet 
(p < 0.03), an effect of diet not seen in females. Perirenal fat pads, expressed either as 
absolute weight or as percentage of body weight were greater in males vs. females 
(p < 0.05). Perirenal and epididymal fat pads were greater in rats with one vs. zero copy 
of the /a allele (p <0.008), as well as rats fed 48% vs. 12% fat diets (p < 0.0001). Females 
exhibited significantly lower plasma glucose, insulin and total cholesterol than males. In 
addition, high fat diet resulted in increased plasma glucose (p < 0.03) in females and 
insulin in males (p < 0.05). Lastly, high fat resulted in decreased concentration of adipose 
and soleus ea2+ -A TPase, while one copy of fa had this effect on soleus alone. The results 
of the present study not only show heterozygote effects of the fa allele, but suggest that 
these effects may be modulated by both gender-related factors and dietary manipulations. 
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B. Introduction 
There are mutant genes in the human population which are responsible for the 
development of obesity and hypertension (1 - 3). If considered recessive, those with two 
· copies of the mutant allele would be rare and grossly obese or hypertensive, while others 
"carry" only one copy and would appear lean or borderline hypertensive, respectively. 
However, if the specific gene, protein product and function have not yet been identified 
it may not be evident if one copy of the mutant allele affects the normal phenotype. 
Depending on the results of the mutation, such as no protein product, unregulated 
protein product or mutant competitive protein product, there may be environmental 
factors which exacerbate or attenuate deleterious effects of heterozygosity (1). 
Genetics and environment have been shown to interact in obesity and 
hypertension in humans (2 - 4). Individuals, with familial dyslipidemic hypertension 
(FDH) who are genetically susceptible to coronary heart disease experience earlier onset 
of hypertension and dyslipidemia with high fat diets (2). Further, high fat feeding has 
been shown to induce or exaggerate insulin resistance and hypertension in both normal 
and obese animal models ( 5 - 11  ). The composition of dietary fat has been found to be 
an important factor in the development of cardiac risk factors ( 4, 12). Saturated fats, 
particularly, myristate (14:0), have been found to be the most atherogenic fats, while 
polyunsaturated fats, such as linoleate (18:2), may even be protective (12). In general, it 
is suggested that dietary intake of saturated fats increases cardiovascular risks more than 
intake of polyunsaturated fats, however over consumption of either is deleterious ( 4 ). 
The obese Zucker rat (fa/fa) is a genetic extreme of obesity and also exhibits 
insulin resistance and elevated blood pressures ( 13 ). This phenotype is relatively 
resistant to environmental manipulations which would otherwise reduce these pathologies 
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when compared to lean animals (Fa/?) (7, 8). In addition, obese animals (fa/fa) are 
relatively sensitive to environmental manipulations which would exacerbate obesity and 
insulin resistance (7). Therefore, studies of environmental effects on modulation of 
phenotypical fa gene expression have proved difficult in obese animals as they are 
already at the phenotypical extreme. Obese Zucker rats (fa/fa) fed an energy restricted 
diet, nonetheless, exhibit an obese body composition (8). While lean Zucker rats 
(Fa/?) seem relatively resistant to high fat diets, obese Zucker rats (fa/fa) appear 
sensitive to high fat feeding (7). 
The fatty mutation in Zucker rats has been considered a recessive mutation (14, 
15). However, recent evidence comparing siblings carrying zero, one or two copies of 
the fa allele show that it is not a purely recessive trait as previously thought ( 16 - 20). 
Until recently it has been impossible to distinguish between genotypes of lean (Fa/?) 
versus obese (fa/fa) Zucker rats until later in development, when phenotypic markers 
( rectal temperature, body weight and fat pad size) are discernible (21 ). In addition, 
distinguishing between lean animals with zero or one copy of the affected gene has 
depended on the known breeding history of parent animals. Therefore, little research 
has been done to show gene dosage effects of the altered allele (fa), but a few studies 
have shown lean heterozygote animals (Fa/fa) to be phenotypically intermediate on 
several physical and metabolic parameters (16 - 20, 22). 
Intermediate values reflecting brown adipose tissue thermogenesis have been 
shown in lean Zucker heterozygotes (Fa/fa) (20). In addition, insulin was increased in 
heterozygote lean (Fa/fa) and obese (fa/fa) compared to homozygote lean (Fa/Fa) 
Zucker rats (17). Inguinal fat pad weight and fat cell size and number in lean Zucker 
heterozygotes (Fa/fa) were also intermediate between obese (fa/fa) and homozygote 
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lean (Fa/Fa) Zucker pups by three weeks of age (19). Furthermore, lipid metabolic 
enzymes, such as lipoprotein lipase and 6-phosphogluconate dehydrogenase, were also 
intermediately produced in adipose and liver tissue. Finally, insulin binding in brain and 
liver is reduced in both lean heterozygote (Fa/fa) and obese (fa/fa) when compared to 
lean homozygote (Fa/Fa) animals (16, 18). 
Recent discovery of a restriction fragment length polymorphism (RFLP) 
recognized by a human genomic subclone sequence (vc85) which segregates with fa in a 
Brown Norway (BN)/Zucker cross, allows identification of obese animals (fa/fa) at an 
early age. Furthermore, lean homozygote (BN/BN) and heterozygote (BN/fa) offspring 
can now be distinguished, but only in subsequent generations of this cross (21). 
Consequently, we sought to demonstrate that: a.) effects of one copy of fa are present 
later in life than previously reported, b.) there are interactions between copy number of 
the fa allele with dietary fat and c.) heterozygous (BN/fa) Brown Norway/Zucker 
offspring may be used as models of obesity, insulin resistance and hypertension 
(Syndrome X) that are susceptible to environmental manipulation. 
C. Materials and Methods 
Animals. Offspring of subsequent generations of a BN/Crl X Crl:Zuc-fa Fl intercross 
were supplied by Pennington Biomedical Research Center (Table 6). Pups were placed 
individually in wire hanging cages. All animals were fed semipurified diet {Agway Prolab 
Rat Mouse Hamster 3000, Syracuse, NY) upon arrival and lived in a controlled 
119 
Table 6. Distribution of BN/Z-fa offspring by sex, genotype, diet and litter. 
Diet Sex Copies fa N Litters represented 
12% Fat diet Female 0 4 1,2,2,4 
1 6 3,4,5,5,6,6 
Male 0 8 1, l,2,2,3,3,4,6 
1 5 3,5,5,6,6 
48% Fat diet Female 0 4 1, 1,2,2 
1 5 1,3,4,5,6 
Male 0 8 1, l,2,2,3,3,3,5 
1 5 1,4,5,6,6 
TOTAL 45 1 - 6 
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environment (21°C) with a 12 hour light:dark cycle. This study was approved by the 
University of Tennessee Institutional Animal Care and Use Committee. 
Genotype assignment. Offspring were genotyped at Pennington Biomedical Research 
Center. High molecular weight DNA was prepared by phenol-chloroform (Autoextract 
Kit, Isogene Biotechnology, Overland Park, KS) extraction from tail segments. DNA was 
digested with the restriction endonuclease Taq_-1 (Boehringer Mannheim, Indianapolis, 
IN) and electrophoresed through 1 % LE agarose gel (Sigma, St. Louis, MO) in 40 mM 
tris(hydroxymethyl)aminomethane acetate and 1 mM EDTA, transferred to nylon 
membranes (Hybond N + ,  Amersham, UK) according to manufacturer's instructions. 
Blots were hybridized with a 2.1 kb subclone vc85 (American Type Culture Collection 
61067), labelled with 32P-alpha-dA TP random priming kit (DECAprime, Ambion, Austin, 
TX) in 10% dextran sulfate, lM NaCl, 1 % sodium dodecyl sulfate and 10 ug/ml sheared 
salmon sperm DNA at 65°C for 16-24 hours. 
Diet. Male and female rats (5 wks) were randomly assigned to a low (12% energy) or 
high (48% energy) fat diet (Table 7). Weekly food intake and body weight were 
recorded for the duration of the seven week study. Coconut oil (Table 8) replaced corn 
starch in the high fat diet, and protein and essential micronutrient content was adjusted 
to be equivalent on an energy basis. Animals were allowed free a�ess to their assigned 
diet and water. Energy efficiency was calculated as weight gain (g) divided by energy 
intake (kcal) throughout the feeding period. 
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Table 7: Components of low (12% energy) and high (48% energy) fat diets 
Component 12% fat diet1 48% fat diet1 
Sucrose 29.9 (g/lOOg) 37.2 (g/lOOg) 
Cornstarch2 35. 1  0 
Coconut oil2 0 19.4 
Casein 20.0 24.8 
Com oil 5.0 6.2 
Cellulose 5.0 6.2 
AIN Mineral mix 3.5 4.3 
AIN Vitamin mix 1.0 1.2 
D-1-methionine 0.3 0.4 
Choline bitartrate 0.2 0.3 
Energy 3.86 (kcal/g) 4.80 (kcalfg) 
1 12% and 48% of energy derived from fat 
2Coconut oil was substituted for cornstarch in the high fat diet. 
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Table 8: Fatty acid composition of the coconut oil used in the diet. 
Fatty acid Percentage 
< 12:0 5.45 
12:0 48.37 
14:0 20.94 
16:0 1 1.27 
18.0 6.66 
18: 1 5.64 
18:2 1.36 
20:0 0.14 
TOTAL 99.83 
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Surgery and blood pressure measurement. After approximately 7 weeks of diet 
treatment each animal was anesthetized with sodium pentobarbital (PB - 50 mg/kg) and 
a femoral arterial catheter (PE 10) was implanted, exteriorized at the nape of the neck 
and stored in a tissue culture cap. Approximately 72 hours post-surgery, blood pressure 
was measured directly via a low volume transducer and Digi-med monitor (Micromed 
Inc. Lexington, KY) in the conscious, unrestrained state. 
Plasma collection and assays. The animals were then anesthetized (50 mg/kg PB) and 
exsanguinated by cardiac puncture of the left ventricle. Plasma glucose, cholesterol, 
triglyceride, and insulin concentrations were determined using the standard glucose 
oxidase, cholesterol, and triglyceride kits (Sigma, St. Louis, MO) and radioimmunoassay 
(INCSTAR, Stillwater, MN) methods, respectively (Appendix B). 
Western blot analysis of ea2+-ATPase. Aorta, soleus and adipose tissue samples were 
washed and minced in phosphate-buffered saline and submerged in equal volumes of 
suspension buffer and 2X gel loading buffer. Samples were then heated at 100°C for 10 
minutes, sonicated and centrifuged. The supernatant was removed and a modified 
Lowry procedure (Appendix B) was performed to determine protein concentrations. 200 
µg of protein samples were loaded and electrophoresed through a 10% sodium dodecyl 
sulfate (SDS)-polyacrylamide gel. Proteins were then electroblotted for 1 hour using 
transfer buffer containing Tris, glycine, methanol and SOS. After blocking, blots were 
incubated in blocking solution containing a 1 : 1000 dilution of the mouse-anti-rat 
monoclonal antibody to the plasmalemmal Ca2+  -A TPase ( Affinity Bioreagents, N eshanic 
Station, NJ) in ascites fluid. After washing 2 times in tris-buffered saline containing 
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Tween 20 (TBST), the blots were incubated in 5 µCi 1251-labelled goat-anti-mouse IgG 
(ICN, ltvine, CA). The blots were then washed 3 times with TBST, dried briefly, and 
exposed to film (NEN Dupont, Wilmington, DE) for 7-10 days. 
Statistical analysis. Analysis of data compiled in this study had to account for highly 
unbalanced groups. Data were analyzed employing the MIXED Procedure of SAS (23). 
Each of the dependent variables ( energy efficiency ratio (EER), plasma insulin, plasma 
glucose, fat pads weights, mean arterial pressure, heart rate, plasma triglycerides, plasma 
cholesteroL glucose to insulin ratio and Ca2+ -A TPase concentrations) were regressed on 
the independent variables diet, sex, genotype, litter, diet and sex, diet and genotype, 
genotype and sex, and diet by sex by genotype. Diet, sex, genotype and interactions were 
considered fixed factors, while litter was considered a random factor. Thus the effect of 
diet, sex and genotype are theoretically applied to all possible litters of BN /Z offspring. 
F statistics for analysis of variance of the fixed factors were computed using Type III 
sum of squares for unbalanced data. 
D. Results 
Weight gain over the seven weeks on diet was greater in males t�an females. In 
addition, males of either genotype on high fat diet gained significantly more weight than 
males on low fat diet. Weight gain in males carrying one copy of fa was greater than 
males carrying zero copy of fa only on the high fat diet (Figure 5). 
Male animals on high fat diets were more energy efficient (weight change/energy 
intake) than those on low fat diets. In addition, males were more energy efficient than 
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females on either diet (Table 9). There was no apparent effect of genotype on energy 
efficiency. 
Perirenal fat pads, expressed either as absolute weight or percentage of body 
weight were greater in animals fed high vs. low fat and in males vs. females on high fat 
diet (Table 9). Similar effects of diet were seen with epididymal fat pads expressed as 
percentage of body weights (Table 10). Moreover, a diet and genotype interaction was 
observed revealing that males with one copy of fa had a significantly greater increase in 
perirenal and epididymal fat pad weights expressed as percentage body weight on high 
fat diet than males with zero copy of fa (Table 10). 
Plasma cholesterol was significantly higher in male than in female animals on 
high fat diet (Table 9). A diet and sex interaction revealed that males responded to high 
fat feeding with increased plasma cholesterol while females did not. Plasma triglycerides 
were not significantly affected by gender, diet or genotype (Table 9 and 10). 
Plasma glucose was increased in males compared to females and in females with 
high fat feeding (Table 9). Plasma insulin was significantly higher in males fed high fat 
diets vs. males fed low fat and females on high fat diet. 
Mean arterial blood pressure was significantly different in males carrying one 
versus zero copy of the fa allele only on high fat diets when paired by litter and analyzed 
by paired t-test (p <0.03). There were no significant differences in heart rate by gender, 
genotype, diet or any interaction. 
Overall, high fat feeding decreased Ca2+  -A TPase protein concentration in soleus 
and perirenal fat (p< 0.03) but not in aorta. In addition, one copy of fa resulted in 
reduced Ca2+ -A TPase protein in the soleus (Figure 6). 
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Mean growth curves of Brown Norway /Zucker male and female 
offspring on low ( 12% energy) and high ( 48% energy) fat diets. The 
weight gain over 7 wks was compared. 1indicates significant 
difference from males, 2indicates significant difference from 12% fat 
diet and 3indicates significant difference from BN/BN, all at p < 0.05. 
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Table 9. Physiological measurements of Brown Noiway /Zucker offspring fed low (12% 
energy) or high ( 48% energy) fat diets. 
GENDER 
DIET 
N 
EER 
PFP % BW 
TC (mg/dL) 
TG (mg/dL) 
Glucose (mg/dL) 
Insulin ( ng/mL) 
MAP (mmHg)1 
HR 
FEMALE 
12% 
10 
0.030±0.003 
0.90±0.143 
79.4±4. 13 
46.4±6.08 
143.9±6.13 
2.43± 1.013 
126±43 
365 ± 183 
48% 
9 
0.030±0.0023 
l.33±0.15b 
75.5±4.38 
48.4±5.88 
161.9±6.3b 
2.43±0.983 
128±58 
355±213 
MALE 
12% 
13 
0.046±0.002b 
0.91 ±0. 143 
86.8±4.03 
50.7±5.68 
158.8±5.8a,b 
4.01± 1 .1  !3 
126±43 
366± 183 
48% 
13 
0.053 ±0.002c 
l.77±0. 13c 
98.8±4.0b 
53.7±5.53 
168.0±5.5b 
6.70±0.96c 
13 1±43 
359± 183 
Values with the same letter (a, b, or c) are not significantly different at p < 0.05. 
1The sample sizes for mean arterial pressure were 8, 6, 10, and 8 as ordered above. 
KEY: N = sample size, EER = energy efficiency ratio (weight change (g)/energy intake 
(kcal)) over 7 weeks, PFP % BW = perirenal fat pads expressed as percent body weight 
TC = total cholesterol, TG = triglyceride, MAP = mean arterial blood pressure, HR = 
heart rate 
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Table 10. Physiological measurements of male Brown Norway /Zucker offspring fed low 
(12% energy) or high ( 48% energy) fat diets. 
DIET 
GENOTYPE 
N 
EER 
PFP % BW 
EFP % BW 
TC (mg/dL) 
TG (mg/dL) 
Glucose (mg/dL) 
Insulin (ng/mL) 
MAP (mmHg)1 
HR 
12% 
BN/BN 
8 
0.04 7 ±0.0023 
0.73±0. 163 
1 .17 ±0. 133 
81.8±4.58 
49.0±6.53 
149.4±6.73 
5.10± l. 19a·b 
127±53 
375±198 
BN/fa 
8 
0.046±0.0033 
1.11 ±0.22a,b 
1.34±0.173 
91. 7 ±6.3a,b 
52.3± 7.73 
168.3 ± 9 _5a,b 
2.93±1.743 
125±68 
355±253 
48% 
BN/BN 
5 
0.053±0.003b 
l .41±0.16b 
1.66±0.13b 
98.9±4.6b 
51.5±6.33 
164.3± 7.2a,b 
5.65± 1.19a,b 
128±53 
366±213 
BN/fa 
5 
0.053±0.003b 
2. 12±0. 19c 
2.30±0. 15c 
98.8±6.3b 
55.8±7.73 
171.8±8.5b 
7.73±1.27b 
134±63 
352±253 
Values with the same letter (a, b or c) are not significantly different at p < 0.05. 
1Sample sizes for mean arterial pressure were 8, 6, 10, and 8 as ordered above. 
KEY: N = sample size, EER = energy efficiency ratio (weight change (g)/ener'5'} intake 
(kcal)) over 7 weeks, PFP % BW = perirenal fat pads expressed as percent body weight, 
EFP % BW = epididymal fat pads expressed as percent body weight, TC = total 
cholesterol, TG = triglyceride, MAP = mean arterial blood pressure, HR = heart rate 
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Densitometric evaluation of soleus Ca2 + -A TPase concentration in 
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significantly different at p < 0.05. 
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A diet by genotype interaction was observed wherein the effect of high fat reduction of 
Ca2+-ATPase was significant only in animals with one copy offa (p < 0.001). 
E. Discussion 
The results of the present study clearly demonstrate effects of gender, high fat 
diet, genotype and interactions of these on physiological variables related to obesity, 
insulin resistance and hypertension (Syndrome X). We have thus begun to characterize 
a potentially useful model for the study of gene-environment interactions in the 
development of cardiovascular risk factors. 
Effects of high fat feeding emerged, regardless of gender or genotype from this 
study. Energy efficiency was increased with high fat feeding in males but not females. 
Furthermore, animals on the high fat diet exhibited greater energy efficiency with 
increased fat storage in perirenal and epididymal fat pads. In addition, fasting plasma 
insulin was significantly higher in males on high fat diet. Thus it appears that 
development of insulin resistance and obesity observed with high fat feeding in several 
other studies may also occur in Brown Norway/Zucker offspring. However, in contrast 
to previous studies of both rats and dogs, high fat feeding alone did not result in 
hypertension (5, 6). This discrepency may be due to differing experimental design with 
respect to the duration of the diets, total fat content and composition of fat in the diets 
(6). 
Interestingly, high fat diet also resulted in reduction of soleus and perirenal fat 
plasmamembrane Ca2+ -A TPase concentrations. Our laboratory has previously found 
relationships between insulin and intracellular calcium regulation in vascular smooth 
muscle (VSM) (24, 25). In cultured VSM cells, insulin results in increased expression of 
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plasma membrane and sarcoplasmic reticulum calcium pumps (24). Moreover, insulin 
increases the recovery to baseline calcium after agonist-induced calcium increases (25). 
This latter effect of insulin is impaired in aortic cells from insulin resistant obese Zucker 
rat (26). 
Furthermore, others have found increases in intracellular calcium enhance 
insulin-mediated glucose transport in skeletal muscle (27) and adipose tissue (28). 
However, when intracellular calcium is increased beyond an optimal range, insulin­
stimulated glucose transport is inhibited (28). Accordingly, the observed decreases in 
ea2+ -A TPase may result in reduced insulin sensitivity secondary to increases in 
intracellular calcium. Conversely, it is also possible that diet-induced insulin resistance 
may result in diminished ability of insulin to stimulate ea2+ -A TPase expression. 
Consequently, further studies are clearly needed to elucidate the mechanism by which 
high fat leads to reduction of this protein in skeletal muscle and adipose tissues. 
There were several effects of gender which remained significant across diets and 
genotypes. Surprisingly, female rats in this study exhibited a marked decrease in energy 
efficiency, or ability to convert caloric intake into body mass, when compared to male 
rats. Consistently, females also had lower perirenal fat pad weights expressed as percent 
body weight. In addition, females had significantly lower plasma insulin and total 
cholesterol than males. These results suggest that female rats are more insulin sensitive 
than males, at least early in development, and may be resistant to metabolic impairments 
resulting in increased risk factors for syndrome X. Consistant with this concept is the 
observation of android obesity in syndrome X, where deposition of visceral fat is 
associated with increased levels of circulating androgens in both male and female 
humans (29, 30). 
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The interactions of diet and gender in this study support further investigation of 
this animal model for the study of obesity and insulin resistance. A closer look at energy 
efficiency revealed that while females were less efficient than males on either diet, males 
consuming high fat were more efficient than males consuming low fat diets. Likewise, 
while females were more insulin sensitive than males regardless of diet, males consuming 
high fat had significantly higher plasma insulins than the males on low fat diets. 
Moreover, while plasma cholesterol was actually somewhat lower in females fed high fat 
compared to females fed low fat diets, it was significantly higher in males fed high fat 
compared to males fed low fat diets. Clearly there is a gender and diet interaction in 
this model which allows female rats to remain relatively insensitive to high fat feeding, 
while increased cardiovascular risk factors (weight gain, increased cholesterolemia and 
increased insulinemia) mimicking syndrome X begin to be present in males fed high fat. 
Unlike gender and diet, genotype alone had only significant effects of increasing 
both epidiymal and perirenal fat pad weights and reducing Ca2+-ATPase concentration in 
the soleus. However, these data demonstrate effects of carrying one copy of the fa allele 
later in development than previously reported (16 - 20, 22) and may be indicative of a 
predisposition to increased adiposity and calcium dysregulation. Truett et al. studied 
siblings carrying zero, one, or two copies of the fa allele at 7 and 14 days of age (22). 
Analysis of gross physical measures revealed a linear effect of fa copy number on body 
weight and inguinal fat pads weights at 7 days of age, thus indicating a codominant effect 
of fa in early development. Quadratic effects of fa copy number began to appear later in 
life, indicating a shift towards recessivity. 
In the present study, it was observed that fa may indeed act recessively in the 
groups that were maintained on normal diets. However, in male animals on high fat 
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diets there were significant phenotypical differences attributable to the copy number of 
fa. High fat diet increased the epididymal fat pads weights of animals carrying one copy 
of fa, while there was no difference between low fat fed and high fat fed animals carrying 
zero copy of the fa allele. In addition, heterozygosity of fa in combination with high fat 
consumption in males resulted in the greatest energy efficiency and the highest fasting 
plasma insulin. Furthermore, males with one copy of fa, on the high fat diet exhibited 
higher blood pressures ( analyzed by paired t-test) than high fat fed male littermates with 
zero copy of fa. Therefore, the copy number of fa, continues to affect the phenotype of 
14 week old male animals under specific (high fat) dietary conditions. Thus, the 
deleterious effects of high fat feeding on cardiovascular risk factors such as weight gain, 
hyperinsulinemia, insulin resistance and hypertension are further enhanced by male 
gender in animals carrying one copy of the fa allele. 
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PART 4 
CONCLUSIONS 
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I. IMPACT OF THIS RESEARCH AND FUTURE DIRECTIONS 
Studies presented here support accumulating evidence from several laboratories 
that insulin is intricately involved in regulation of calcium metabolism. Conversely, 
recent evidence also predicts a role of calcium in insulin regulation. This reciprocal 
relationship is very likely altered in insulin resistant states and in conditions where 
calcium-handling abnormalities are primary. Further studies should include elucidation 
of the metabolic targets (such as Ca2+ ATPase and Glut4) which are affected by both 
insulin and calcium and defining the intermediates ( such as PPl and calmodulin) 
involved. 
The final study reported here clearly demonstrated gene (fa) and environment 
(diet) interactions which have previously been ignored in a historically valuable animal 
model of Syndrome X. Due to the difficulty of controlling the environment of human 
subjects, animal models are at times the only solution to isolating gross physiological 
effects of the environment. The BN /Z model appears to be useful for studying 
Syndrome X, especially in light of the observed gender effects and gene-environment 
interactions. 
The research presented here adds to a very large pool of knowledge regarding 
the relationships among obesity, insulin resistance and hypertension. Despite the wealth 
of information describing cardiovascular risk, we are still searching for cause and effect 
in this disease process. Moreover, with each new finding, there are yet more 
unanswered questions. This is why the work presented within this document is so 
important. Examination of molecular and cellular mechanisms, systems integration, and 
whole animal interactions with environment is crucial considering the prevalence of 
cardiovascular disease. 
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With the recent cloning of the ob gene (which codes for a yet-undefined humoral 
factor that appears to affect satiety and fat storage) and the association of ob with db 
(the mouse homologue for fa) as a putative receptor, the causative nature of many 
genetic obesities will, in the next ten or so years, be defined. This will also be of value 
for understanding cases of Syndrome X which are not solely genetically determined. 
However, it is doubtful that simple cures ( such as those aimed at regulation or return of 
protein products) will allow us to control all of the associated symptoms of Syndrome X. 
Understanding the effects of insulin resistance on individual tissues (through transgenic 
studies) and the development of Syndrome X in the aging population should help us 
strive towards preventative goals, regardless of genetic predisposition. The genetic 
revolution must be tempered by the understanding that genetic influence never rules out 
environmental effects, as organisms do not exist without both. 
For future research, I will continue to investigate the roles of genetics and 
environment in obesity and cardiovascular disease. Specifically, in light of our recent 
findings, I will begin by further investigating the mechanisms responsible for the gender 
differences we have observed. I would like to examine development profiles in both 
intact female and male animals compared with castrated animals of both genders to 
elucidate the role of steroid hormones ( androgens, estrogen and cortisol regulation of 
gene expression) in Syndrome X (See literature review for references) . 
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APPENDIX A 
Fluorometi;y theoi;y and general procedures adapted from the Hitachi F-2000 
Fluorometer (Naperville, IL) owners manual: 
When a molecule (Fura-2-Ca2+) is excited by light ( excitation wavelengths = 340 and 
380 nm) and electrons move to an excited state, optical energy is emitted ( emission 
wavelengths = 510 nm) called FLUORESCENCE (emission is longer than excitation due 
to vibrational energy) as the electrons move back towards the ground state. 
Fluorescence intensity at both excitation wavelengths is measured and the 
concentration of calcium is computed by the computer internal to the fluorometer using the 
following equations: 
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*Digitonin permeabilizes the cell membrane and EGTA chelates calcium away from Fura-2. 
There are four important components to be analyzed from each tracing shown in 
the text: Baseline, peak response, rate of recovery to baseline and the area under the 
response curve. 
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APPENDIX B 
Sigma Enzymatic Glucose Determination (Procedure No. 510, St. Louis, MO): 
This procedure is based on two enzymatic reactions. In the first, glucose, water 
and oxygen react in the presence of the enzyme glucose oxidase to form gluconic acid 
and hydrogen peroxide. In the second the hydrogen peroxide reacts with o-dianisidine 
(colorless) in the presence of the enzyme peroxidase to form oxidized o-dianisidine 
(brown). 
Twenty-five microliters of standard (100 mg/dL) or plasma were added to 0.5 
mL of water, followed by 5 mL of the enzyme-color reagent solution ( containing glucose 
oxidase, horseradish peroxidase and o-dianisidine) and mixed. The tubes were incubated 
at 37° C for 45 m at room temperature. Absorbances of the standard and samples were 
read in reference to a blank (water and enzyme-color reagent) in a Beckman 
spectrophotometer (DU30, Fullerton, CA) at 475 nm. The sample values were then 
calculated utilizing the following formula: 
Plasma Glucose [mg/dL] = Aiest /Astandard x 100 
Triglycerides and cholesterol were studied using Sigma kits with similar design, although 
different reagents, with a colorimetric shift detected by spectrophotometry and compared 
to standard. 
Incstar Insulin 1251 Radioimmunoassay (RIA) Kit (06130, Stillwater, MN) and rat 
standard 25 ng/mL: 
The concept behind RIA is relatively simple. Binding sites (B) for a hormone (in 
this case, insulin) are provided by an antiserum establishing [Btowl. They are exposed to 
a low concentration of labelled hormone [1251-insulin] and to the same unlabelled 
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hormone (insulin) to be measured. Thus the concentration of 1251-insulin is a function of 
the dilution of 1251-insulin by unlabelled insulin. The concentration of bound radioactive 
tracer {1251-insulin•B] in consideration of the total radioactivity in the absence of 
hormone 1251-insulin•B0] .  Results are obtained by comparing sample outcomes to a 
standard curve utilizing various concentrations of unlabelled insulin standards. 
Two hundred microliters of plasma or standard, 100 µL antiserum containing 
first antibody and 100 µL 1251-insulin were combined and incubated for 20 hours at 4° C. 
A second antibody precipitating complex was then added (0.5 mL) and the tubes were 
spun for 20 minutes at 760 x g, following a 25 minute incubation at room temperature. 
The supernatant was removed and the orifice of the tubes was blotted. The samples 
were then counted on a Packard Cobra-II gamma counter (Meriden, CT) for 10 minutes 
each. Sample concentrations of insulin were computed by the counter in comparison 
with the standard curve after consideration of total counts (100µ.L usl-insulin only) and 
non-specific binding (200 µL O standard, 100 µL usl-insulin and 0.5 mL precipitating 
complex). 
Modified Lowzy Procedure from: Lowzy et al, Journal of Biological Chemistcy 
195 1; 193 :265: 
Protein treated with alkaline copper sulfate forms a copper-protein chelate which 
allows copper to act as a catalyst for protein reduction of phosphot.ungstic acid and 
phosphomolybdic acid (Folio reagent) to form a chromophore detectable in the visible 
spectrum. Tyrosine and tryptophan residues are oxidized resulting in the reduction of 
the Folin reagent and color formation. 
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Dilutions of 0.01 % Bovine Serum Albumin (BSA) in 0.9% saline were utilized to 
create a standard curve of O (blank), 10, 20, 40, 80 and 100 µg/µL. Samples were 
diluted 1000 fold in 0.9% saline. One mL of diluted standards or samples were mixed 
and incubated with 3 mL of Lowry reagent (containing 2% Na2C03, 0.4% NaOH, 0. 16% 
sodium tartrate and 1.0% SOS mixed 100: 1 with 4.0% CuS04•5H20) for 15 minutes at 
room temperature. Three hundred µL of Folin-Ciocalteu reagent premixed 1: 1 with 
deionized H20 was added, tubes were mixed and further incubated for 45 minutes at 
room temperature. Absorbances were read at 660 nm on a Beckman spectrophotometer 
(DU30, Fullerton, CA) against the blank and protein concentration was determined 
using the following formula: 
Concentration = Absorbance of sample/K 
K = constant = average (absorbance of standards/concentration of standards) 
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